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ABSTRACT
The pulmonary adenoma susceptibility 1 (P as I) locus affects 
inherited predisposition and resistance to chemically induced lung 
tumorigenesis in mice. A/J and C57BL6/J mouse strains carry the 
susceptibility and resistance allele, respectively. In the present 
study we identified and genotyped 64 polymorphisms in the PasI 
locus in 29 mouse inbred strains in order to reduce the region 
containing the PasI locus, and we succeeded in delimiting the PasI 
locus to a minimal region of 468kb containing six genes (B catl, 
Lrmp, Cascl, Ghiso, Kras2 and Lmn-rsl). That region defined a core 
PasI haplotype (A/J- and C57BL/6J-type) with 42 tightly linked 
markers, including intragenic polymorphisms in five genes (Bcatl, 
Lrmpf Cascl, Ghiso and Kras2) and amino-acid changes in three 
genes (Lrmp, Cascl and Lmn-rsl). mRNA expression study of these 
candidate genes revealed that, in (A/JxC57BL/6J)Fl mouse lung 
tumors, the Lmna-rsl gene was completely downregulated, whereas 
allele-specific downregulation of the C57BL/6J-derived allele was 
observed at the Cascl gene, suggesting the potential role of these 
genes in tumor suppression. These first results indicate a complex 
multigenic nature of the PasI locus, and point to a functional role for 
both intronic and exonic polymorphisms of the six genes of the PasI 
haplotype in lung tumor susceptibility.
Then we continued by testing functional activity of candidate genes 
in vitro. In vitro colony formation assay of human lung cancer cell 
lines A549 and NCI-H520 transfected with the allelic variants of the 
four genes revealed allele-specific modulations of colony numbers by 
Lm na-rsl and Cascl, but not by Lrmp and Ghiso. We found that 
inhibition of clonogenicity by allelic forms of PasI candidate genes 
was not mediated by induction of apoptosis.
These findings provide evidence that allelic variants of mouse PasI 
candidate genes differentially modulate growth of human cancer
Chapter 1 INTRODUCTION
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1.1 CANCER GENETICS: BASIC KNOWLEDGE
Cancers are derived from single somatic cells and their progeny in 
which regulatory mechanisms for proliferation have been disrupted 
(Ponder, 2001). Malignant cells have several qualities that 
distinguish them from their normal counterparts. They are immortal, 
often grow more rapidly than normal cells of the same origin, and 
fail to exhibit normal cell-cell interactions (Bale and Li, 1997) 
Tumorigenesis in humans is a multi step process. Steps or "hits" are 
mutations or other alterations of genes involved in regulation of cell 
growth and cell interactions. Mutations and alterations may occur by 
random chance during DNA synthesis and cell replication, after an 
exposure to environmental carcinogens, or they may be inherited as 
germline mutations.
Hanahan and Weinberg in 2000 suggested that, in perhaps all types 
of human tumors, cancer cell genotype is a manifestation of six 
essential alterations in cell physiology that collectively dictate 
malignant growth (Fig.l):
1. Self-Sufficiency in growth signals. Normal cells require 
mitogenic growth signals (GS) before they can move from a 
quiescent state into an active proliferative state. Many of the 
oncogenes act by mimicking normal growth signaling.
2. Insensitivity to antiarowth signals. Multiple antiproliferative 
signals operate to maintain cellular quiescence and tissue 
homeostasis in a normal tissue. Cancer cells must evade these 
antiproliferative signals if they are to prosper.
3. Evading apoptosis. Programmed cell death - apoptosis- 
together with the rate of cell proliferation determines the 
ability of tumor cell population to expand in number. Cancer 
cells can acquire resistance to apoptosis.
4. Limitless replicative potential. Perhaps all types of mammalian
cells carry an intrinsic, cell-autonomous program that limits
their multiplication. This program must be disrupted in order
10
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for a clone of cells to expand to a size that constitutes a 
macroscopic life-threatening tumor.
5. Sustained anqiooenesis. The oxygen and nutrients supplied by 
the vasculature are crucial for cell function and survival, 
obligating virtually all cells in a tissue to reside within 100 ^m 
of a capillary blood vessel. The ability to induce and sustain 
angiogenesis seems to be acquired in a discrete step (or 
steps) during tumor development, via an "angiogenic switch" 
from vascular quiescence.
6. Tissue invasion and metastasis. Primary tumor masses spawn 
pioneer cells that move out, invade adjacent tissues, and 
thence travel to distant sites where they may succeed in 
founding new colonies.
wawnsjiiaiM
■
.
Sustained
angiogenesis
Tissue invasion 
& metastasis
Figure 1 Acquired capabilities of cancer. From Hanahan and Weinberg, 
2000.
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The order in which these capabilities are acquired seems likely to be 
quite variable in all cancer types and subtypes. A particular genetic 
lesion may confer several capabilities simultaneously, decreasing the 
number of distinct mutational steps required to complete 
tumorigenesis.
Otherwise, when a capability is acquired through the collaboration of 
two or more distinct genetic changes, the total number necessary 
for completion of tumor progression is increased.
Several factors can influence the evolution of a cancer.
These factors reflect genetic or epigenetic alterations, each 
conferring one or another type of growth advantage, that drive the 
progressive transformation of normal cells into highly malignant 
derivatives. These events are somatic events but in many of the 
inherited cancer syndromes one of the events is inherited.
1.1.1 Inherited  and sporadic cancer
Some individuals are genetically predisposed to a particular type of 
cancer (Ponder, 1990). Most common hereditary cancers are 
sporadic and the genetic alterations responsible for their genesis 
take place over several cell generations; nevertheless, 5 to 10% of 
human tumors are hereditary, with a rapid development (Russo et 
a/., 2000). Family history is important to recognize clinically 
inherited predisposition. A family history of cancer, early age of 
onset and absence of known carcinogen exposure, suggest an 
underlying genetic disorder. In terms of family history, it is possible 
to distinguish three categories of inherited predisposition to cancer. 
(Table 1 in Ponder, 2001)
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Table 1 Inherited predisposition to cancer. From Ponder, 2001.
• Inherited cancer syndromes: the incidence is 1-2% at most. 
These syndromes consist in rare or unusual cancers or 
combinations of cancer. Sometimes these syndromes are 
associated with specific phenotypes that are attributable to the 
predisposition gene. A predisposing mutation is present in all 
somatic cells and in the germline, which enables the 
transmission of risk to the next generation.
• Familial cancers: the incidence is up to 10%. This category 
includes cancers that tend to cluster in families but, because 
of the lack of markers for the predisposed phenotype, there 
may be doubt about the presence of inherited predisposition in 
any given family.
• Inherited predisposition without evident family clustering: in 
this case, there is an inherited disposition with low penetrance 
so that familial clusters are rare. The distribution of these 
cases in the population is probably determined by the 
combined effects of multiple genetic and non-genetic risk 
factors.
In the last few years a number of genes, whose germ-line mutations 
cause a highly penetrant familial predisposition to cancer have been 
mapped on the human genome, and some have been cloned and
identified. In humans the frequency of alleles that confer an 
inherited predisposition to cancer is variable, being about 1:100,000 
in the case of retinoblastoma (RBI), 1-2:10,000 in neurofibromatosis 
(NFI), 1:1,000 in familial breast cancer (BRCA1), and 1:1,000 in 
hereditary nonpolyposis colorectal cancer (HNPCC).
The greatest discoveries to date in the genetics of common inherited 
cancers relate to breast, ovarian, and colorectal cancer. In particular 
there have been studies of mutations in two genes for breast and 
ovarian cancer (BRCA1 and BRCA2), the APC gene for familial 
adenomatous polyposis, and several mismatch repair genes, which 
correct errors in DNA that arise after replication, for hereditary non­
polyposis colon cancer (Emery eta l., 2001).
All cancers are genetic in origin because they arise from mutations 
in a single somatic cell, but the genetic changes in sporadic cancer 
are confined to a particular tissue. In inherited cancers, a 
predisposing mutation is present in all somatic cells and in the 
germline, which enables the transmission of risk to the next 
generation. Mutations in BRCA1, BRCA2, APC and the genes related 
to hereditary non-polyposis colon cancer are inherited in an 
autosomal dominant fashion. However, BRCA and the genes 
associated with hereditary non-polyposis colon cancer (and a few 
APC mutations) show incomplete penetrance, and they predispose a 
carrier to develop specific cancers. Additional genetic, 
environmental, and hormonal factors determine the ultimate 
development of cancer in mutation carriers (Emery et al.r 2001).
The pattern of genetic alterations differs between cancer of different 
types, and of the same type. This genetic pattern is not random and 
it is influenced not only by genetic background, but also by 
environmental exposures.
Genetic variation that acts either within or outside the cancer cell 
may determine the outcome of interaction with exogenous 
carcinogens. An example is provided by the risk of cutaneous
melanoma which is increased by exposure to the sun in individuals 
with a fair skin or who have many naevi.
1 .1 .2  Polygenic inheritance of predisposition to cancer
Polygenic inheritance of predisposition to cancer is demonstrated in 
experimental animals for different tum or types. Genetic 
susceptibility to different types of cancer is determined by 
inheritance of multiple cancer predisposition and resistance alleles, 
whose chromosomal locations have been found by genetic linkage 
analysis.
Epidemiological evidence indicates that in many cases of sporadic 
cancers, first degree relatives of cancer patients show an excess risk 
of cancer when compared with the general population. This evidence 
may suggest the existence of a polygenic inheritance of 
predisposition to particular types of cancer (Dragani eta l., 1996). 
Several types of genes are involved in carcinogenesis. Normal cell 
regulation results from balance between the function of growth- 
promoting genes and growth-suppressing genes. When the former 
type of gene is "activated" through amplification or mutation to a 
hyperfunctioning form, it exerts a dominant positive effect of cell 
growth. Such genes are known as "oncogenes". The latter type of 
gene is known as a "tumour suppressor". Loss of function of both 
homologous copies of a tumour suppressor gene has a powerful 
growth-promoting effect. Loss of just one copy typically has very 
little effect. Other genes that may be altered in cancer cells include 
those involved in DNA repair and in programmed cell death.
Tumour suppressor genes were identified through their role in 
familial predisposition to cancer. These genes are known to be 
critically important in growth control of both sporadic and hereditary
tumours. The majority of hereditary cancer predisposition is 
attributable to germline mutations in tumor suppressor genes. 
Expression of protooncogenes in normal cells appears to be carefully 
regulated. Different oncogenes are turned on/off at different steps of 
the cell cycle, at different stages of embryologic development, and 
in different cell types. Protooncogenes function as messengers in the 
pathway by which external stimuli received at the surface lead to 
DNA synthesis, cell growth, and division (Bale and Li, 1997).
1 .1 .3 Cancer m odifier genes
Variation in phenotypic expression is a feature of many dominantly 
inherited single-gene disorders. An example of this kind of disorder 
is Neurofibromatosis type 1 (NF1) that is notable for its variable 
expressions. Although the major diagnostic features of cafe-au-lait 
patches, cutaneous neurofibromas, and Lisch nodules are each 
present in more than 90% of cases of puberty, the number of 
lesions varies greatly. Furthermore, there are a number of 
characteristic features which only occur in a minority of cases such 
as severe learning difficulties, scoliosis, optic gliomas, epileptic 
seizures, and pseudoarthrosis. Some of this variation in phenotypic 
expression could reflect different mutations in the NF1 gene. Almost 
half of all NF1 cases are the results of new mutations and a number 
of different mutations have been reported. Variation in the NF1 
mutation is not the only source of variation, because there are also 
considerable differences in expression between members of the 
same family. In 1979, Carey et al. demonstrated that three-quarters 
of families showed marked differences in severity of NF1 between 
individuals. The remainder of the phenotypic variation could be due 
to other modifying genes, environmental factors, or some 
combination of these. The term "modifying gene" is used to denote
any gene unlinked to the NF1 locus whose genotype correlates with 
the NF1 phenotype (Easton eta l., 1993).
Nathanson et al. in 2002 observed that the substantial variability in 
penetrance of breast cancer due to germline mutations in BRCA1 
has led to speculation that inheritance of BRCA1 mutation alone may 
not completely describe the observed cancer phenotype. 
Considerable variation in the degree of breast cancer risk associated 
with a BRCA1 mutation has been observed and this suggests that 
modifiers of BRCA 1 penetrance may exist.
Cancer modifier loci are defined as genetic loci involved in fine- 
tuning the tumor phenotype through allele specific effects on cancer 
development, e.g., stimulation or inhibition of tumour development 
and/or tumour progression. Cancer modifier loci may comprise a 
"null" allele, with no effects on tumour phenotypes, and a 
"susceptibility" or "resistance" allele, which affect tumour phenotype 
in a dominant, codominant or recessive way.
The study of mouse cancer modifier loci might serve as the basis for 
understanding the genetic and biochemical mechanisms of polygenic 
inheritance of cancer predisposition/resistance. Identification of 
homologous cancer modifier loci in humans might provide a step 
toward the development of diagnostic, preventive, and therapeutic 
strategies that target these loci (Dragani, 2003). Cancer modifier 
loci affecting specific stages of the tumorigenesis process have been 
mapped in the experimental models where the tumor-initiation and 
tumour-promotion/progression phenotypes are clearly defined. For 
example, in lung tumorigenesis, the PasI and Pari loci affect both 
tumour multiplicity and size, whereas Par2 and Par4 act specifically 
on tumor multiplicity, and Papgl and Slue affect only tumor size. 
(Gariboldi eta /.1993, Manenti et al., 1996 and Tripodis et al., 2001 
in Dragani, 2003) Cancer modifier loci may affect either single or 
multiple stages of carcinogenesis.
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1.2 GENETIC DETERMINANTS OF POLYGENIC TRAIT
The major challenge for medical genetics for the next decade is to 
systematically identify genes responsible for the hereditary 
contributions to a range of disorders that are not inherited in a 
simple Mendelian fashion but that have a definite or probable 
genetic component. Complex diseases are thought to involve 
susceptibility genes at multiple loci, known or unknown 
environmental factors and, commonly, incomplete penetrance of 
susceptibility genes. This "complex" trait includes a large fraction of 
the common causes of disability and death in Western society such 
as atherosclerosis, hypertension, psychiatric disorders, Alzheimer 
disease, type I and type I I  diabetes, asthma, rheumatoid arthritis, 
and probably significant components of the general aging process. 
These disorders may be oligo- or polygenic, and environmental and 
stochastic developmental and immunologic processes may play a 
major role in the development of these diseases (Weissman, 1995). 
The term "complex trait" refers to any phenotype that does not 
exhibit classic Mendelian recessive or dominant inheritance 
attributable to a single gene locus. In general, complexities arise 
when the simple correspondence between genotype and phenotype 
breaks down, either because the same genotype can result in a 
different phenotype or different genotypes can result in the same 
phenotype (Lander and Schork, 1994).
There are some problems in the study of complex traits:
• Incomplete penetrance and phenocopy. Some individuals who 
inherit a predisposing allele may not manifest the disease 
(incomplete penetrance), whereas others who inherit no 
predisposing allele may nonetheless get the disease as a result 
of environmental or random causes (phenocopy).
• Genetic (or locus) heterogeneity. Mutations in any one of 
several genes may result in identical phenotypes, such as 
when the genes are required for a common biochemical
18
pathway or cellular structure. For these reasons medical 
geneticists typically have no way of knowing whether two 
patients suffer from the same disease for different genetic 
reasons, at least until the genes are mapped. Genetic 
heterogeneity hampers genetic mapping, because a 
chromosomal region may cosegregate with a disease in some 
families but not in others. Genetic heterogeneity should be 
distinguished from allelic heterogeneity, in which there are 
multiple disease-causing mutations at a single gene. Allelic 
heterogeneity tends not to interfere with gene mapping.
• Polygenic inheritance. Some traits may require the 
simultaneous presence of mutations in multiple genes. 
Polygenic traits may be classified as discrete traits, measured 
by a specific outcome, or quantitative traits, measured by a 
continuous variable whose level may be set by the combined 
action of individual quantitative trait loci.
The methods available for genetic dissection of complex traits fall 
neatly into four categories: linkage analysis, allele-sharing methods, 
association studies in human populations, and genetic analysis of 
large crosses in model organisms such as the mouse and rat.
Linkage analysis involves proposing a model to explain the 
inheritance pattern of phenotypes and genotypes observed in a 
pedigree. It  is the method of choice for Mendelian diseases, such as 
Huntington disease and cystic fibrosis, for which the diagnosis is less 
ambiguous and there is a near one-to-one correspondence between 
genotype and phenotype, however applications to complex traits can 
be more problematic.
Linkage analysis is the starting point for positional cloning. Families 
in which a disease phenotype segregates are analyzed using a group 
of DNA polymorphisms. The earliest and still most fully documented 
success in which linkage mapping alone led to the gene was cystic
19
fibrosis in 1989. At that time, the polymorphic markers were 
restriction fragment length polymorphisms; today hundreds of 
thousands of single nucleotide polymorphisms are available through 
the sequencing of the human genome.
The nature of linkage mapping limits resolution to the order of 1-10 
cM. In favourable cases (such as cystic fibrosis), the pattern of 
crossovers in the region of the gene among the cohorts studied 
leaves only a few predicted genes, all within about 1 cM (~  1 Mb), 
as likely candidates (Botstein and Risch, 2003).
Allele-Sharing methods involve studying affected relatives in a 
pedigree to see how often a particular copy of chromosomal region 
is shared identical-by-descent that is inherited from a common 
ancestor within the pedigree.
Association studies do not concern familial inheritance patterns at 
all, but they are case-control studies based on a comparison of 
unrelated affected and unaffected individuals from a population. 
Association studies are not well suited to whole-genome searches in 
large, mixed populations. Because linkage disequilibrium extends 
over very short distance in an old population, one would need tens 
of thousands of genetic markers to cover the genome.
There are some differences between linkage analysis studies and 
association studies. Associations studies test whether a disease and 
an allele show correlated occurrence in a population, whereas 
linkage studies test whether they show correlated transmission 
within a pedigree. Associations studies focus on population 
frequencies, whereas linkage studies focus on concordant 
inheritance.
Experimental crosses of mice and rat offer an ideal setting for 
genetic dissection of mammalian physiology. The power of 
experimental crosses is most dramatically seen in the ability to 
dissect quantitative traits into discrete genetic factors. Systematic 
quantitative trait locus (QTL) mapping has only recently become
possible with the construction of dense genetic linkage maps for 
mouse and rat.
In the past decade, quantitative trait locus (QTL) mapping has 
identified hundreds of chromosomal regions containing genes 
affecting asthma, atherosclerosis, diabetes, hypertension, obesity 
and other complex phenotypes. An important goal of QTL mapping is 
to identify the genes underlying these polygenic traits and to gain a 
better understanding of their physiology and biochemistry. Korstanje 
and Paigen in 2002 suggested that QTL mapping of complex traits is 
a promising technique and that the harvest of QTL genes is just 
beginning.
The analysis of QTL has also been made easier by recently 
developed statistical tools for detecting gene-gene interactions. 
Identifying QTL genes in animal models has more often relied on 
positional cloning followed by the use of transgenic or knockouts. 
QTL found in animal models may predict their location in the human 
genome.
The primary difficulty in identifying QTLs is that any single QTL 
explains only a small fraction of the phenotypic variation and thus 
the phenotype-genotype correlation is low. QTL analysis can be 
separated into two stages: ( 1) from phenotype and genotype to 
QTL, and (2) from QTL to gene. (Tab 2)
Stage 1 consists of correlating genetic markers (i.e. detectable DNA 
polymorphism, such as microsatellites and single nucleotide 
polymorphisms [SNPs]), with a phenotype in a segregating 
population. Therefore, stage 2 is required to assign the phenotype to 
a single gene (and not a locus) preferably by means of functional 
assay. (Darvasi and Pisante-Shalom, 2002)
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sib pairs; extended fami­
lies; discordant sib pairs; 
etc.)
Association analysis (case- 
central; TDT, etc.)
Linkage and association 
analysis with experimental 
crosses (intercross; back- 
cross; recombinant inbied 
strains; congenics; etc.)
Linkage and association 
analysis with existent 
populations (half-sibs; full 
sibs; etc.)
From QTL to gene
Humans
Model organisms
Positional intoimation
Functional information
Positional infbunation
Functional information
Transgenics
Knockouts
Reciprocal hemizygosity3
Table 2 Main stages and strategies in QTL mapping From Darvasi and 
Pisante-Shalom, 2002.
1.2.1 Linkage disequilibrium (LD)
Mendelian diseases (e.g. cystic fibrosis) result from defects in one 
gene. However, it is suspected that most common diseases (e.g. 
hypertension) are 'polygenic', meaning that variation in the 
presence/absence of the disease is attributable, at least in part, to 
polymorphism of multiple interacting genes.
An allele of one of these 'susceptibility genes' may contribute to 
disease in certain genetic and environmental contexts, but not in 
others (Kirk e ta /., 2002).
Polymorphism represents the transient state between the origin of 
genetic variation by mutation and the loss of variation by fixation of 
either the ancestral or derived state. Today, the expression 'single 
nucleotide polymorphism' (SNP) is often applied to variable sites for 
which the rarer base is present within the population at > 1%
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frequency, whereas germline polymorphism with a frequency < 1% 
are typically referred to as 'mutations'
Traditional linkage analysis, based on allele sharing between 
relatives, identifies broad chromosomal regions that are likely to 
contain disease genes. However, the resolution of these methods is 
limited by the number of recombination events in typical pedigrees 
and is impractical for positional cloning efforts in complex disease. 
Fine mapping within the broad regions identified by allele-sharing 
methods is a major challenge. Gene mapping strategies based on 
linkage disequilibrium fLD^ are expected to have much greater 
resolution, and should be able to capitalize on dense SNP maps as 
they become available. (Risch and Merikangas, 1996)
LD mapping can precisely locate genes of small effect and could be 
used to identify common disease genes in genomewide scans or to 
reduce the number of candidate genes in a region in which linkage 
has been established. (Lander 1996; Risch and Merikangas 1996; 
Collins et al. 1997; Lai et al. 1998). In the presence of common 
disease alleles, or when the frequency of rare alleles is increased 
through selection, the sample sizes required for LD studies are much 
smaller than those for equivalently powered linkage studies (Risch 
and Merikangas, 1996). Unlike traditional linkage studies, the power 
of LD mapping depends strongly on disease-allele frequencies and 
on the extent of disequilibrium between marker and disease alleles 
(Muller-Myhsok and Abel, 1997; Tu and Whittemore, 1999).
LD is the correlation of character states among polymorphic sites. 
(Lynch and Walsh, 1997 in Kirk et al., 2002). The simplest 
explanation for LD is linkage coupled with insufficient passage of 
time to randomize the character states by meiotic recombination.
As ancestral haplotypes propagate through a population, their 
physical length is reduced by recombination events. Recombination 
events between markers separated by very short distances are very 
rare. Individuals inheriting a disease mutation from a common, but 
possibly distant, ancestor are expected to share a region of the
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ancestral haplotype in which the mutation originated. Markers within 
this shared haplotype are non-randomly associated with the disease 
and each other, and are said to be in linkage disequilibrium. 
Association studies using family based controls can distinguish 
between linkage disequilibrium and other sources of association, 
such as population admixture (Abecasis and Cookson, 2000). 
Association studies using LD to identify susceptibility genes have 
achieved some recent success. Proof of principle experiments using 
a high-density SNP map in genomic regions already known to 
contain susceptibility genes for complex diseases have confirmed 
known genes or identified new ones (Rioux et a l.,2001; Hewett et 
al., 2002; Horikawa et al., 2000 in Kirk et al., 2002).
These successful association studies are ' candidate aene' 
approaches, where the location of the susceptibility gene is either 
already known or suspected. This experimental design is based on a 
two-step LD methodology (Roses, 2000 in Kirk et al., 2002). In the 
first step, a low-density SNP map (i.e. 'picket fence') of the whole 
genome is used to identify a region(s) containing the potential 
susceptibility gene(s). Once the region is identified, a high-density 
SNP map is used to home in on the susceptibility gene within the 
region.
1.3 LUNG CANCER
Lung cancer is the leading cause of cancer death in the world 
(12.3%  of all cancer), causing more than one million deaths each 
year. The incidence and mortality rates are highest in the United 
States and Europe and continue to increase in industrialized 
countries (Rivera, 2004). Its leading cause is tobacco smoke, a 
complex mixture containing many carcinogens that play a role in the 
genetic and epigenetic changes occurring in the respiratory 
epithelium during the multistage process of lung carcinogenesis. The
many lung cancer-specific carcinogens (including polycyclic aromatic 
hydrocarbons and nitrosamines) in the particular matter of tobacco 
smoke have to be metabolized before they are either secreted or 
can bind to DNA with the formation of adducts. DNA adducts may be 
repaired or lead to apoptosis. I f  they persist, miscoding mutations in 
key genes, such as p53 or RAS may cause genetic instability, 
leading to further mutational damage and eventually to cancer. (Fig. 
2 in Minna et a l.r 2002)
About 40% of all new lung cancers occur in former smokers, who 
remain at high risk of developing lung cancer for many years after 
they stop smoking.
A part from HIV/AIDS, tobacco is the only major cause of death that 
is increasing rapidly. Worldwide, smoking caused about three million 
deaths in 1990, out of a total of 30 million adult deaths from all 
causes, and it will cause about 10 million in 2030, out of a total of 
about 60 million (Peto et a!., 1999).
Nicotine
addiction
Smoking
Metabolic
Carcinogens activation DNA Miscoding
(PAH, NNK etc) adducts
Metabolic detoxification 
(GSTM1 etc)
Excretion
(p53; Kras  etc)
Repair
Apoptosis
Cell death
Normal
Figure 2 Nicotine addiction, tobacco smoke carcinogenesis, and the 
pathogenesis of lung carcinomas. From Minna et a!., 2002.
Non-small cell lung cancer (NSCLC) accounts for 80 to 85% of all 
new cases of lung cancer. Less than 15% of patients with lung 
cancer survive their disease.
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1.3.1 Histological Types
The term lung cancer is used to denote carcinomas arising from the 
epithelium of the respiratory tract.
Histooathoqenesis
The histopathogenesis of lung cancer is incompletely understood and 
the true site of origin of lung cancer is unclear.
Two theories exist: (1) a pleuripotential cell (stem cell) theory, 
advocated by Auerbach, of one pleuriotential cell from which all cell 
types evolve, and (2) a small-cell theory, advocated by Yesner, of a 
type of small-cell neoplasm that undergoes transformation and 
evolves into the other cell types. (Fig. 3)
Adenocarcinoma Brofichnolo-Epidermoid Large Cell
Undifferentiated
... Car'HjAr
Small-Cell 
Alveolar cancer Lung cancer 
(KCC III)
Atypical 
Carcinoid 
(KCC II)
Typical 
Carcinoid 
(KCC I)
Cancer
Kulehitzky Cell
Stem Cell
Glandular Cell
Figure 3 The stem cell theory of lung cancer pathogenesis as proposed by 
Auerbach.
The true site of origin of small-cell lung cancer is difficult to identify. 
I t  is also difficult to know the origin of adenocarcinomas or large-cell 
carcinomas because they may come from the bronchial epithelial 
surface or the underlying mucous glands. There is, however, 
increasing evidence that tumors arise from a common mucosal,
pleuripotential stem cell. The heterogeneity found in various cell
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»types of lung cancer, particularly large-cell anaplastic carcinoma and 
various small-cell lung cancer tumors, may explain the variations in 
response to therapy and may be explained by the common stem cell 
theory.
Lung cancers arise after a series of molecular and morphological 
events. The molecular events commence in histologically normal 
epithelium and show a specific sequence (Hirsch et al. 2001 in Minna 
et al., 2002). A microscopie based microdissection of epithelial 
tissue followed by allelotyping of smoking damage to lungs in lung 
cancer patients or current or former smokers without lung cancer 
revealed hundreds of thousands of lesions (~ 90,000 cells in size) 
containing clonal abnormalities of allele loss , occurring in both 
histologically normal as well as abnormal (e.g. hyperplasia, 
dysplasia or carcinoma in situ) respiratory epithelium (Park et al., 
1999 in Minna e ta l., 2002). (Fig. 4)
Early Intermediate Late
Normal Hyperplasia Squamous Dysplasia Carcinoma Invasive
Epithelium Metaplasia In Situ Carcinoma
Figure 4 Progressive morphological and molecular changes during the 
multistage development of squamous cell lung carcinomas. From Minna et 
a/., 2002.
In 1982, the World Health Organization classified bronchial 
carcinoma into four m ajor histologic types (squamous cell 
carcinomas, adenocarcinoma, small cell carcinoma and large cell 
carcinoma), rare tumor types, and tumors consisting of more than
»
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0one histologic pattern. However, for clinical, therapeutic and 
biological reasons, lung cancers are classified into small cell (SCLC) 
and non-small cell (NSCLC) subdivisions.
D
Squamous cell carcinomas account for approximately one-third of all 
lung cancers. They usually originate within a central bronchus, and a 
^ central cavitation from necrosis is common. This kind of cancer
generally grows slowly with little likelihood of distant spread.
Adenocarcinomas account for approximately 30% to 45% of lung 
0 cancers. These tumours originate within the periphery of the lung, in
particular they arise from the progenitor cells of bronchioles (Clara 
cells) or alveoli (Type I I  pneumocytes) or from mucin producing 
cells, and tend to metastasize early to regional lymph nodes and to
3
distant sites, particularly the brain. Adenocarcinoma is the most 
common lung cancer in the world, and its frequency is increasing 
rapidly especially in women, people who have never smoked, and in 
young people.
3
The term bronchioalveolar carcinoma is applied to those 
adenocarcinomas believed to arise from the terminal bronchioles 
and alveoli and represents approximately 2% to 4% of all lung 
3 cancers. Usually, the presence of these tumors is not correlated with
smoking.
Larae-cell carcinoma represents a less differentiated form of the 
^ other NSCLC (non-small cell lung cancer). This tumor accounts for
approximately 9% of all lung cancers. The name derives from the 
large cells with large nuclei and prominent nucleoli that characterize 
the tumor. Large-cell carcinomas often have poor differentiation and 
3 no evidence of maturation. Giant- and spindle-cell carcinomas, that
have been classified as a variant of large-cell carcinoma, carry poor 
prognoses and account for less than 1% of lung cancers.
3
Small-cell lung cancer fSCLQ accounts for 10% to 15% of all lung 
cancers. This kind of tumor has a very aggressive clinical course, 
with frequent widespread metastases. SCLC is not amenable to 
surgical treatment in its early stages. Small-cell lung cancers 
typically are situated in a peribronchial location, and they infiltrate 
the bronchial submucosa and peribronchial parenchyma tissues. 
SCLCs have neuroendocrine features and arise from cells 
programmed to differentiate along these lines.
Without treatment, small cell carcinoma of the lung has the most 
aggressive clinical course of any type of pulmonary tumor, with 
median survival from diagnosis of only 2 to 4 months.
Since the 1930s, cytologic examination of sputum has been used for 
the diagnosis of advanced and early lung cancer.
Squamous and SCLC arise mainly from the central airways, while 
adenocarcinomas (including bronchioloalveolar cancer) are 
peripherally located. Sputum samples contain exfoliated cells shed 
from the oropharynx and larger respiratory passages, so the' 
cytologic analysis of sputum is helpful for the detection of central 
tumors arising from the larger exfoliated bronchi such as squamous 
cell and small-cell carcinomas. Cells from peripheral tumors arising 
from the smaller airways, such as adenocarcinomas, can be 
detected only occasionally in sputum sample (Gazdar and Minna, 
1999). There is no squamous epithelium in the normal lung, and 
tumors arise from metaplastic changes resulting from smoking.
Genetic predisposition to developing lung cancer 
Approximately 11% of tobacco smokers develop lung cancer. This 
suggests that some genetic factors may influence the risk for lung 
cancer among those who are exposed to carcinogens. (Fong et al.r 
2005).
Tokuhata and Lilienfeld in 1963 and Ooi et al. in 1986 found 
increased risk for lung cancer in both smoking and non-smoking
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relatives of lung cancer patients. It was found that smoking interacts 
with a family history of lung cancer. Familial aggregation studies of 
lung cancer provide indirect evidence for the role of genetic 
predisposition. More common genetic polymorphisms at genes, 
coding for enzymes involved with metabolism of exogenous 
compounds, including carcinogens, are more likely to have a large 
quantitative effect on the risk of lung cancer. The combination of 
two lung tumor associated polymorphisms results in an additive risk 
of lung cancer and this suggests genetic heterogeneity and 
polygenic inheritance of lung cancer risk.
Using candidate gene and genome wide approaches it has been 
hypothesised that lung cancers have accumulated 20 or more clonal 
genetic and epigenetic alterations as a multistep process. These 
genetic changes include activation of proto-oncogenes such as myc, 
Kras, EGFR, Her-2/neu, and BCL-2 as well as the inactivation of 
TSGs (Tumor suppressor genes) like p53, Rb, FHIT, and p l6 .  
Genetic alterations affecting TSGs usually involve two events: the 
loss of large chromosomal DNA regions of one parental Dna, and a 
smaller mutational event affecting the second allele. The early clonal 
genetic lesions that occur in smoking damaged preneoplastic 
bronchial epithelium are being identified, as are the molecular 
differences between small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLS), and between tumors with different clinical 
outcome.
1.4 MOUSE MODEL
Over the past century, the mouse has developed into the premier 
mammalian model system for genetic research. Scientists from a 
wide range of biomedical fields have gravitated to the mouse 
because of its close genetic and physiological similarities to humans,
as well as the ease with which its genome can be manipulated and 
analyzed.
Although yeasts, worms and flies are excellent models for studying 
the cell cycle and many developmental processes, mice are far 
better tools for probing the immune, endocrine, nervous, 
cardiovascular, skeletal and other complex physiological systems 
that mammals share. Like humans and many other mammals, mice 
naturally develop diseases that affect these systems, including 
cancer, atherosclerosis, hypertension, diabetes, osteoporosis and 
glaucoma. In addition, certain diseases that afflict humans but 
normally do not strike mice, such as cystic fibrosis and Alzheimer's, 
can be induced by manipulating the mouse genome and 
environment.
1.4.1 Mice for cancer studies
The inherited genetic determinants of cancer risk remain largely 
unknown and the identifications of cancer predisposing genes 
directly in humans is very difficult. Moreover, individual variation in 
the development of cancer in humans, even given identical 
exposures or identical germline changes in specific predisposing 
genes, offers the possibility of profound insight into host factors that 
modify the development of cancer. Determining those factors in 
humans is a daunting task (Klausner, 1999). The fact that mice can 
and do get cancer has fostered the important role of the mouse in 
cancer research.
These models are helping us to understand this disease as a 
complex genetic trait and thus to identify the multiple genetic 
variant alleles involved in pathways that affect individual cancer 
susceptibility. The mouse offers significant advantages for
identification of tumor susceptible genes and is useful for the study 
of complex influences of genetic background on tumor susceptibility. 
A large portion of the mouse genome shows regions of homology 
and conserved syntenies with the human genome, and comparative 
genetic maps between mice and humans have been used to predict 
the location of human and murine disease genes on the basis of 
their mapping in other species. (Dragani et al., 1995)
Compared to the total span of evolution, the lineage that gave rise 
to mouse and man diverged relatively recently. It  was found that 
the essential functions of most genes, in general, and most, if not 
all, genes identified as important in human cancer, are likely to be 
very similar between mouse and man.
Furthermore, the use of mice as a model offers significant 
advantages:
• the size of the "families" for the analysis is restricted only by 
the dimensions of the animal house;
• the ability to control environmental exposure;
• the relatively low cost;
• the availability of dozens of inbred strains, outbred mice, 
recombinant inbreds, recombinant congenics, transgenic, 
knockouts, knockins, and even clones.
1.4 .2  Mouse inbred strains
A useful mouse model for the study of cancer is mouse inbred 
strains. They are obtained by crossing brothers and sisters for at 
least 20 generations. They are homozygous at almost every genetic 
locus thus representing fixed, unique genotypes that can be 
repeatedly accessed as homogeneous populations, with defined 
allelic composition and predictable phenotypes.
Although some intermixing between strains has occurred, the inbred 
rodent strains differ genetically from each other and represent good 
animal models of human diseases. The distribution and frequency of 
different alleles, including those related to cancer predisposition, 
may be sufficiently represented in laboratory strains compared with 
the wild groups from which they were derived.
Many inbred strains of mice are available, they have a predominance 
of resistance or susceptibility alleles, and exhibit extreme sensitivity 
or resistance to tumor development in certain tissues.
Opportune crosses between susceptible and resistant inbred strains 
can give valuable information about the dominant or recessive 
nature of resistance, as well as providing indications about the 
number of the genes involved or their locations in the genome. 
(Balmain and Nagase, 1998)
1.4 .3  Mice for the study of Lung cancer
Different mouse strains exhibit different propensities to cancers, 
whether they are spontaneous or induced.
Spontaneous lung cancer develops in approximately 3% of wild 
mice. The Mus musculus strains most sensitive to the spontaneous 
development of lung tumors include A/J and SWR; strains with 
intermediate sensitivity include Balb/c and 020; relatively resistant 
strains include CBA and C3H; and the most resistant strains include 
DBA and C57BL/6. (Lynch, 1926; Shimkin, 1955 in Tuveson and 
Jacks, 1999)
Some studies have revealed that tumor predisposition in different 
strains is controlled by multiple loci which control fundamental 
processes such as the tumor growth rate, ability to stimulate 
angiogenesis, or the risk of malignant progression (Hirst and 
Balmain, 2004). These different loci have been identified through
the evaluation of crosses between different inbred strains or species 
of mice (Tuveson and Jacks, 1999).
Mice susceptible to spontaneous lung tumors are also often sensitive 
to chemically-induced lung cancer. Induction of lung tumors with 
chemical carcinogens is very reproducible and almost invariably 
results in pulmonary adenomas and adenocarcinomas (Shimkin and 
Stoner 1975; Malkinson 1989). Furthermore, mice exposed to 
environmental carcinogens, develop tumours by a multistage 
process very similar to that seen in humans. Genetic alterations 
detected in mouse tumours involve genes (such as RAS, cyclin D l, 
RBI (pRb), TP53 (p53) and CDKN2A (p l6 ), that are the most 
commonly altered genes in human tumours.
Spontaneous lung tumors in mice are similar in morphology, 
histopathology, and molecular characteristics to human 
adenocarcinomas, but in contrast to human lung cancer, the 
majority of murine lung tumors are histologically early lesions such 
as hyperplasias and adenomas, which may originate from either 
Clara cells or alveolar type 2 cells that line alveoli (Thaete and 
Malkinson, 1991 in Tuveson and Jacks, 1999). These similarities 
underline the importance of the use of mice as a model for the study 
of human cancer.
In most cases murine lung tumors develop relative benign 
adenomas and rarely more aggressive adenocarcinomas and exhibit 
limited vascularisation and very few, if any, metastasize.
There is no relationship between the susceptibility of any given 
mouse strain to lung tumors and its susceptibility to tumors of other 
organs.
Mouse models for lung cancer can serve as a valuable tool not only 
for understanding basic lung tumor biology but also for the 
development and validation of new tumor intervention strategies as 
well as for identification of markers for early diagnosis.
Individual cancer risk is determined by combinations of resistance or 
susceptibility alleles inherited through the germline. The polygenic
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nature of this inheritance pattern and the variable penetrance of the 
genes will, of course, mask any clear-cut familial clustering and 
complicate studies designed to find the loci involved by classical 
linkage analysis.
Genetic loci, which modify lung tumorigenesis, have been identified 
by crossing different inbred strain of known susceptibility and 
resistance to lung tumorigenesis.
The mouse inbred model is useful for statistical methods that take 
account of the fact that multiple genes make different quantitative 
contributions to the phenotype. Quantitative trait locus (QTL) 
mapping is an important method and during the last few years has 
accelerated the analysis of polygenic susceptibility to various 
diseases. Using QTL mapping, a large number of mouse tumor 
modifier loci have now been mapped that control the size, growth 
rate or number of lesions that develop, or can influence different 
stages of tumorigenesis (Balmain and Nagase, 1998).
Rare mutations or polymorphisms, which have major effects on 
tumour growth or survival, contribute to only a small fraction of 
tumours in the human population.
Highly penetrant mutations in genes such as BRCA1/2 are 
responsible for a proportion of cancers that show familial 
aggregation, and mouse models of such genes have provided many 
fundamental and unexpected insights into tumorigenic processes. 
(Hirst and Balmain, 2004).
1.5 BACKGROUND AND A IM  OF THE PROJECT
The present project aims to clone candidate genes for the 
Pulmonary adenoma susceptibility 1 (Pasl) locus, that represents 
the major quantitative trait locus (QTL) affecting inherited 
predisposition to lung tumorigenesis in mouse.
In our laboratory, by using (LD) analysis in 21 strains of known 
susceptibility to lung cancer and by assembling a YAC contig, we 
mapped the Pasl locus to a ~1.5-M b region on distal mouse 
chromosome 6. Our results, based on haplotype and phenetic 
analysis, suggest that the Pasls susceptibility allele is shared by 
several mouse-inbred strains of independent origin, which show 
either high or intermediate predisposition to lung tumorigenesis. We 
have previously mapped in the A/J mouse (a strain that is highly 
susceptible to lung tumorigenesis) the Pasl locus to the distal region 
of chromosome 6. (Gariboldi. et al. 1993). Independent studies with 
the A/J strain have confirmed the major role of Pasl in mouse lung 
tumorigenesis and have also supported the fact that the quantitative 
trait locus (QTL) peak for Pasl is localized around Kras2. (Devereux 
et al. 1994; Festing et al. 1994; Manenti et al. 1995) As in many 
QTL studies, the linked region is too wide (> 10 cM) to undertake 
positional cloning of the causative gene. We hypothesize that the 
Pasls allele originated from a single founder and we designed a 
linkage disequilibrium (LD) study in mouse strains to test this 
hypothesis and to eventually narrow the candidate region for Pasl. 
Herein, it was reported that several markers located in the telomeric 
region of chromosome 6 exhibit significant LD with the genetic 
predisposition to lung cancer development. (Manenti e ta /.,1999). 
According to the Ensemble database, five known genes map in this 
region: the branched-chain aminotransferase cytolic 1 (Bcatl), the 
lymphoid-restricted membrane protein (Lrm p ), the unnamed 
493046P12Rik transcript, the transforming protein p21 (Kras2) and
36
the unnamed 4933403M 22Rik transcript. Protein sequence 
comparison by BLAST showed that the 4933403M22Rik gene 
encodes a protein containing an intermediate filament tail domain 
related to lamin A, therefore, it was provisionally named Lmna-rsl 
(lamin A-related sequence 1). The 493046P12Rik gene encodes a 
growth hormone-inducibile soluble protein with no known protein 
domains; the gene was provisionally named Ghiso.
Using a different program to identify coding regions in the genome 
(NIX analysis package), we identified and then cloned a new gene 
mapping between Lrmp and Ghiso. This gene resulted the mouse 
homologues to the human AK001783 transcript and corresponds to 
the recently identified Cascl gene (Zhang et al., 2003), except for 
an additional 70bp in the 5'-UTR. (Manenti et al., 2004).
The present project aims to identify and characterize allelic variants 
of candidate mouse genes mapping in the restricted pulmonary 
adenoma susceptibility 1 (Pasl) locus region.
The milestones of this project were:
1. To narrow the Pasl containing region by: (a) discovering new 
simple sequences length polymorphism (SSLPs) and single 
nucleotide polymorphism (SNPs) in the region around Kras2 
gene; (b) LD analysis in 29 strains susceptible or resistant to 
lung tumorigenesis; (c) analysis of recombination of Pasl 
region in (CxB)RI mice.
2. To analyse genetic polymorphism of the candidate genes 
mapping in the minimal region in mouse inbred strains of 
known susceptibility (A/J) and resistance (C57BL/6J) to lung 
tumorigenesis.
3. To test functional activity of candidate genes in vitro, by 
subcloning them in to a mammalian expression vectors and 
transfecting them into human cancer cell lines in vivo for: (a) 
clonogenic assay experiment; (b) cell count experiment; (c) 
gene level, expression.
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2.1 ANIMAL AND TREATMENT
2.1 .1  Mouse strains and DNAs
A panel of 29 genomic DNAs from mouse inbred strains, plus DNAs 
of 13 CxB RI lines were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA). C57BL/6J and A/J mice were also from The 
Jackson Laboratory.
2 .1 .2  Lung tum or induction
FI hybrids (ABF1) of male C57BL/6J and female A/J crosses were 
treated intraperitoneally with urethane (BDH, Poole, UK) dissolved in 
water (1000 mg/kg body weight) at 4 weeks of age and observed 
until 50-60 weeks of age, when the mice were killed. Normal lungs 
from untreated A/J and C57BI/6J male mice of about 6 months of 
age were used for RNA preparation. Lung tumors and normal tissue 
were excised, immersed in RNAIater (Qiagen, Valencia, CA, USA) 
and maintained at -20°C.
2.2 ID E N T IF IC A T IO N  AN D A N A L Y S IS  OF G E N E T IC  
VARIATIONS
In A/J and C57BL/6J mice, I carried out a nucleotide sequence 
analysis of genomic fragments for a total length of about 20000 bp 
in the region of mouse Chromosome 6 spanning D 6 In t2 0  to 
D 6 In t4 5 ,  corresponding to the region from 145.027489 to
146.035280 Mb according to Ensembl Mouse release 13.30.1 
(http://www.ensembl.org/).
Genotype analyses were performed using the polymerase chain 
reaction (PCR) technique and two different kind of genetic markers 
were used:
SNP (Single Nucleotide Polymorphism)
SSLP (Single Sequence Length Polymorphism)
In all, 65 genetic markers were used in genotyping 29 inbred 
strains.
In the 29 strains, SNPs were analysed either by allele-specific 
oligonucleotide hybridization (ASO) or by direct sequencing, whereas 
SSLPs were analysed by polyacrilamide gel electrophoresis or by 
agarose gel electrophoresis.
2 .2 .1 SNP analysis
We identified SNPs in genes and in genomic DNA fragments.
All PCR primers used in this study were designed using the Primer 3 
software (http://www.aenom e.wi.m it.edu) and purchased from 
MWG Biotech, Ltd (Ebersberg, Germany). To generate new SNPs, 
the nucleotide sequence of the chromosomal region was analysed by 
the NIX program to identify putative exons. PCR primers were 
designed in the genomic regions surrounding the putative exons and 
amplified in A/J and C57BL/6J parental strains.
SNP identification by sequence analysis
Sequencing was performing using an ABI PRISM automatic DNA 
sequencer (Applied Biosystem), and compared using the fragment 
Assembly System contained in the Genetics Computer Group (GCG)
software package (Wisconsin Package Version 10.2, Madison, WI, 
USA). When a polymorphism was found between the two sequences 
(SNP), two oligonucleotides were designed covering the region 
where the polymorphism was present, and these oligonucleotides 
were used to analysed the 29 DNAs by ASO hybridization.
ASO hybridization
Oligonucleotide hybridization has the potential to provide a method 
of detecting single-base changes within genomic DNA. (Corner et 
al., 1982). Originally carried out on total genomic DNA, ASO is now 
used exclusively to establish the presence or absence of a specific 
mutation in PCR-amplified fragments of genomic DNA.
Probes are constructed from sequence spanning the variant 
nucleotide site. ASO probes are typically 15-20 nucleotides long and 
are normally employed under hybridization condition at which the 
DNA duplex between probe and target is stable only if there is a 
complementary perfect base between them. Typically, this involves 
designing the oligonucleotides so that the single nucleotide 
difference between alleles occurs in a central segment of the 
oligonucleotide sequence, thereby maximizing the thermodynamic 
instability of a mismatched duplex. For this work allele-specific 15- 
mer oligonucleotides empassing the SNP were 5'-end-labeled with 
[y-32 P]dATP (3000 Ci/mM) (Amersham, Branchburg, NY) and T4 
polynucleotide kinase (New England Biolabs, Beverly, MA).
The ASO procedure consists in spotting the denatured PCR-amplified 
fragment on to a nitrocellulose membrane and hybridised, in 
presence of tetramethylammonium chloride (TMAC), with the probes 
labelled with a radioactive isotope. After allowing sufficient time for 
probe-target heteroduplex formation, the probe solution is decanted, 
and the membrane is washed to remove excess probe that may 
have become non-specifically bound to the filter. It is then dried and 
exposed to an autoradiographic film.
2.2 .2  SSLPs analysis
Simple sequence length polymorphisms consist of short tandem 
repeats whose units are generally 2-6 bp in length. They are known 
to distribute somewhat uniformly throughout the genome and to 
allow for a greater information content per locus than SNPs. 
(Dietrich et al., 1992)
SSLPs are used to be the method of choice for genetic mapping in 
humans, mice and rats, due to their exceptionally high rate of 
polymorphism and their relative ease of use. In mouse and rat, the 
markers make it feasible to map the entire genome in any cross 
between laboratory strains. (Dietrich et al., 1992)
In this work, SSLP markers were typed with PCR primers and 25 
radioactive PCR cycles (55°C annealing temperature); results were 
scored on 6% denaturing polyacrilamide gels.
2.2 .3  Fine-mapping recombination breakpoint in CxB R I line
(CxB) RI lines were derived from inbred Balb/c and C57BL/6J strains 
by intercrossing individuals from the F2 generation and then 
inbreeding for at least 20 generations of brother-sister mating. All 
mice of a particular RI line are genetically identical and homozygous 
at all loci, with approximately half the loci derived from C57BL/6J 
and half from Balb/c.
The genotypes of the distal region of Chromosome 6 of CXB RI 
strains ( http ://w w w . i nform atics.iax. ora ) were retyped for 
confirmation and compared with the lung tumor susceptibility data 
of the lines (Malkinson and Beer, 1984).
The CxB5 RI line was genotyped using 45 markers flanking the Pasl 
region, in order to precisely define the extension of the C57BL/6J- 
inherited genome around the Kras2 gene.
2.3 Pasl CANDIDATE GENE ID EN TIFIC A TIO N
The genomic region between markers D6Int24  and D 6 In tl5  (Pasl 
core haplotype) was extensively analyzed to identify all putative 
coding regions based on both homology search and gene prediction 
program present in the NIX analysis package. The mRNA sequences 
of Bcatl (AK013888), Lrmp (NM_008511), Ghiso (AF412300), Kras2 
(NM_021284) and Lmna-rsl (AK016641) were retrieved from the 
Genebank. Computational sequence analysis techniques, BLAST and 
NIX, were used to assemble the Cascl gene (Acc. #AY485607, 
AY485608). The accuracy of this prediction was evaluated by PCR 
analysis of cDNA with primers located in the middle of putative 
exons. The 5' end of the Cascl gene was determined by 5' RACE 
using the Sure-RACE™ panels (OriGene Technologies, Rockville, MD, 
USA).
The sequences of the six genes were PCR-amplified from normal 
lung cDNA of A/J and C57BL/6J mice with the following primer sets: 
B c a t l ,  5 ' - ATTCCAACG AT G GAG A AT GG - 3 ' ,  5 ' -
TCTTCTGTGGCACCGTCAC-3', Lrmp, 5 '-CTGACACCCATCTCATGTGC- 
3 ', 5 ' -GAAGGAAACGTTAAAATCCAAGG-3 ' ,  C a s c l ,  5'- 
CTCACCGGAAGACTACAGTGC-3', 5 '-GAACGCCTGGTGCTCTTAAA-3, 
G h i s o ,  5 ' - T C T G A G C A A G C T G T C G T C T G - 3 ' ,  5 ' -  
TGGTGCAATGATTGGTCAG-3, Kras2, 5'-GGAGAGAGGCCTGCTGAAA- 
3', 5 '-AAGTGTGCCTTAAGAAAGAGTACAAA-3, L mn a - r s l ,  5'- 
CTCTGCCAGCCATGATGAA-3', 5'-TTTCATGGCTTTCCATTTTCTT-3. PCR 
products from the two mouse strains were sequenced and compared 
for polymorphism.
2.3.1 Allele-specific expression of candidate genes in mouse 
lung tum ors
Normal and lung tumor samples were lysed in 700 \x\ of lysing 
solution using the MM 300 mixer mill (Retsch GmbH & Co., Haan, 
Germany). Total RNA was extracted according to the RNeasy Midi kit 
(Qiagen, Valencia, CA) protocol, including a DNase I treatment 
performed directly on the column (see below).
PolyA+ mRNA was prepared by mixing total RNA with Oligotex 
suspension (Qiagen, Valencia, CA). Aliquots of polyA+ mRNA were 
reverse-transcribed using oligo(dT) primers and Superscript™ for 
RT-PCR (Invitrogen, Carlsbad, CA). The first strand cDNAs were 
used for expression analysis of candidate genes by a semi- 
quantitative PCR, adjusting the number of PCR cycles to avoid 
saturation of PCR amplification. All reactions were performed in a 
final reaction volume of 12 pi containing IX  GeneAmp buffer, 1.5 
mM MgCh, 5 pmoles of each primer, 200 pM of dNTPs and 0.6 U of 
AmpliTaq Gold (Applied Biosystems, Foster City, CA). Thermocycling 
was performed on the Gene Amp PCR System 9700 (Applied 
Biosystems). Primer sets were designed to obtain a PCR product 
170-400 bp in size. The Gapdh gene was amplified with primers 5'- 
TGTTCCTACCCCCAATGTGT-3' and 5'-GTGGAAGAGTGGGAGTTGCT- 
3', producing a 179-bp fragment, and used to normalize the amount 
of cDNA in each sample. Candidate Pasl genes were RT-PCR- 
ampl i f ied with the fol lowing primers:  B c a t l , 5 '-
ATTCCAACGATGGAGAATGG-3', 5'-TCTTCTGTGGCACCGTCAC-3, 
L r m p  , 5 ' - A C G C T G A G G A C G A G A G A A G T - 3 ' ,  5 ' -
T G C T C T G T T G G C T C T T C T G A - 3 ' ,  C a s c l ,  5 ' -
TGAAGCTGCTGAGTGAAGCA-3, 5'-ACTAGCACCCAGCCCTTCAC-3', 
Gh i s o ,  5 ' - T CA T GT AT AAAA GT GGA TC AAT T CC- 3 ' ,  5 ' -  
TGGTGCAATGATTGGTCAG-3, Kras2, 5'-GGAGAGAGGCCTGCTGAAA- 
3 ', 5 '-  ACCATAGGCACATCTTCAG-3,  L m n a - r s l ,  5 '-
CCTATCCACTGGAAGCAAGC-3, 5'-TTTCATGGCTTTCCATTTTCTT- 3'.
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PCR products were loaded on 2.5%  agarose gels, stained with 
ethidium bromide, and photographed with a CCD camera for image 
analysis and quantitation.
For allele-specific gene expression, RT-PCR products containing 
SNPs were sequenced with both the forward and reverse primers. 
The fol lowing pr imer sets were used: L r m p ,  5 '-
C ATC G CTTC ATC AG C AC CTA- 3', 5 CTC AG A AAG G CTG G G CTTC - 3', 
C a s c l  , 5 ' - G C A G G A G G A G G A G G A G A G A C - 3 ,  5 ' -  
T G T T C A A A G G C C T G G T T C T T  - 3 ' ,  G h i s o  5 '-
TCATGTATAAAAGTG G ATCAATTCC- 3', 5 '-TG GTG CAATGATTG GTCAG - 
3 ,  K r a s 2  5 ' - GGAGAGAGGCCT GC T GAA A- 3 ', 5 ' -
ACCATAGGCACATCTTCAG-3. The same Kras2 primers also allowed 
detection of Kras2 mutations at codon 61 by nucleotide sequence 
analysis of the PCR product.
Sequence pherograms were analyzed and the heights of peaks at 
the SNP position were evaluated.
2.4 STATISTICAL ANALYSIS
According to their susceptibility to lung tumorigenesis, mouse 
strains were placed into two phenotype groups: the first group 
contained resistant strains and the second group contained 
susceptible and intermediate strains. Linkage disequilibrium between 
strain segregation of marker alleles and lung tumor susceptibility 
was evaluated by Fisher's exact test provided by the SAS software 
(SAS, 1998). P values were transformed to their negative 
logarithms, and a significant LD was considered if the -logP >2 (P 
< 0 .01).
Statistical analysis of cell counts in our transfection, were performed
DO
by univariate analysis of variance using SPSS 10.1 software (SPSS 
Inc., Chicago, IL).
2.5 CANDIDATE GENES ANALYSIS
2.5 .1 Cell lines
Human non-small cell lung carcinoma-derived cell line A549 and 
NCI-H520 were purchased from American Type Culture Collection 
(Rockwill, MD). Cells were grown in RPMI-1640 medium (Cambrex) 
supplemented with 5% FCS, at 37°C in a 5% CO2 humidified 
atmosphere.
Human embryonic kidney cells (HEK-293T) were maintained in 
Dulbecco's modified Eagle medium (Cambrex), supplemented with 
10% FCS, at 37°C in a 5% CO2 humidified atmosphere.
2.5.2C loning of allelic variants in a m am m alian expression  
vector
O Cascl, Ghiso, Lrmp, and Lmna-rsl full-length transcripts derived
from normal lung tissue of A/J or C57BL/6 mice were PCR-amplified
for subcloning in the eukaryotic pEF6/V5-His-TOPO cloning vector
(Invitrogen). The following primers located 5' and 3' of the
0  respective coding regions to include the natural ATG start codon and
end just ahead of the TGA stop codon to produce a chimeric
recombinant protein containing the V5His epitope at the C-terminus
were used: C a s c l ,  5'-GTGAGCGTTCCTGCTCTGC-3', 5'-
0  G G A A T A G C T G A G G A C G C G G A T A - 3 ' ;  G h i s o ,  5 '-
GT G A A A AT G G CCA ATT CGT- 3', 5'-GACTTTGGTATCTGAATAGTAACG-
3'; L r m p , 5 ' - C T C A G C C C A T G C T C T G T G T A - 3 ' ,  5 ' -
O C A C T G G C G G T G G T C C A T C A - 3 ' ;  L m n a - r s l  , 5' -
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CTCTGCCAGCCATGATGAA-3', 5 '-TGACTTTGCTTTCI I I I ICTTGGTC- 
3'.
All reactions were performed in a final volume of 50 pi containing IX  
GeneAmp buffer, 1.5 mM MgCh, 5 pmol of each primer, 100 pM of 
dNTPs and 1.2 U of AmpliTaq Gold (Applied Biosystems). 
Thermocycling was performed on the Gene Amp PCR System 9700 
(Applied Biosystems).
Recombinant expression vectors were sequenced, and clones 
containing full-length inserts in the correct orientation and without 
PCR-induced mutations were used for cell transfections. DNAs of the 
selected recombinant plasmids were prepared and purified using the 
Plasmid Midi Kit (Qiagen).
2 .5 .3  RNA expression
A549 and NCI-H520 cells seeded in 60-mm dishes at 5x10s 
cells/well were transiently transfected with 3 pg recombinant 
plasmid DNA and 6 pi SuperFect (Qiagen) according to the 
manufacturer's protocol.
Superfect Transfection Reagent is a specifically designed activated 
dendrimer possessing a defined spherical architecture, with 
branches radiating from a central core and terminated at charged 
amino groups. Superfect Reagent assembles DNA into compact 
structures, optimizing the entry of DNA into the cell. Superfect-DNA 
complexes possess a net positive charge, which allows them to bind 
to negatively charged receptors (e.g. sialylated glycoproteins) on 
the surface of eukaryotic cells. Once inside, Superfect Reagent 
buffers the lysosome after it has fused with the endosome, leading 
to pH inhibition of lysosomal nucleases. This ensure a stability of 
Superfect-DNA complexes and transport of intact DNA to the 
nucleus.
Cells transfected with the empty vector were used as control. The 
transfections were stopped after 24h, 48h and 72h, cells were 
pelleted and stored at -80°C . The pellets were used for RNA 
extraction by RNeasy Midi Kit (Qiagen, Valencia, CA). This 
technology combines the selective binding properties of a silica-gel- 
based membrane with the speed of spin technology. A specialized 
high-salt buffer system allows up to 1 mg of RNA longer than 200 
bases to adsorb to the RNeasy silica-gel membrane. Samples were 
disrupted in buffer containing guanidine isothiocyanate and 
homogenized. Ethanol is added to the lysate, creating conditions 
that promote selective binding of RNA to the RNeasy silica-gel 
membrane. The sample is then applied to the RNeasy column. 
Residual DNA is removed using the RNase-Free DNase Set. Total 
RNA binds the membrane, contaminants are efficiently washed 
away, and high-quality RNA is eluted in RNase-free water. The RNA 
concentration and purity were determined by measuring the 
absorbance at 260 nm (A26o) in a spectrophotometer. A same 
quantity of RNA was used to isolate PolyA+ mRNA by Oligotex mRNA 
Mini Kit (Qiagen). cDNA was synthesized from polyA+ mRNA using 
SuperScript-III reverse transcriptase (Invitrogen, Carlsbad, CA). 
First-strand cDNAs were used for expression analysis of candidate 
genes by semiquantitative PCR. All reactions were performed in a 
final reaction volume of 12 \x\ containing IX  GeneAmp buffer, 1.5 
mM MgCI2, 5 pmol of each primer, 100 ^M of dNTPs, and 0.6 U of 
AmpliTaq Gold (Applied Biosystems, Foster City, CA). Thermocycling 
was performed using the Gene Amp PCR System 9700 (Applied 
Biosystems). Primer sets were designed to obtain PCR products of 
140-400 bp in size: Gapdh: 5'-GAAGGTGAAGGTCGGAGTC-3', 5'- 
G A A G A T G G T G A T G G G A T T T C - 3 ' ;  L R M P ' .  5 '-
GAGTGAACACCGTCCCTCAT-3', 5'-AAAGACTTGGCTTCCTTGTCC-3'; 
C a s c l : 5'-TATTTACTGAGATTCAAATACAAATTAAGG-3', 5 '-
A G G G C C A T C T G T C G A T A A G C - 3 ' ;  G H I S O  : 5 '-
GCGTGCCGGAAAGTATGTTA-3', 5'-AGTAGGGCAGCTCAGGGATT-3';
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and L M N A - R S 1 :  5 ' -AGAAGGAAATCCCACCAACC-3' ,  5' -
TTGAGTTGACTGCTTATTGCTTTT-3'. PCR products were loaded on 
2.5% agarose gels, stained with ethidium bromide, and 
photographed with a CCD camera for image analysis and 
quantitation.
2 .5 .4  Colony form ation assays
We performed a kill curve to determine the appropriate 
concentration of Blasticidin to use for the selection of resistant cells. 
A549 and NCI-H520 cells were seeded in 12-multi-well plates at 
1.2xl04 cells/well and different concentrations of antibiotic were 
added to the medium. The kill curve revealed that the concentration 
of Blasticidin is different for the two cell lines in particular it is 
5pg/ml for A549 cells and 2 pg/ml for NCI-H520 cells.
A549 and NCI-H520 cells seeded in 6-multi-well plates at 3 x l0 5 
cells/well were transfected with 2pg recombinant plasmid DNA and 4 
pi SuperFect (Qiagen) according to the manufacturer's protocol.
Cells transfected with the empty vector were used as a control. Two 
days after transfection, the appropriate concentration of antibody 
was added and transfectant clones were selected after 17 days for 
A549 and 26 days for NCI-H520 cells. Blasticidin-resistant clones 
were either fixed with methanol (100% ) and stained with 10%  
Giemsa, or treated with trypsin, pelleted by centrifugation, 
resuspended in RPMI-1640 medium and counted using a Burker 
chamber. We repeated at least three independent experiments.
2 .5 .5  Protein and apoptosis analysis
HEK-293T cells in 100-mm dishes were transiently transfected with 
5pg recombinant plasmid DNA using the calcium phosphate
precipitation method. After 24, 48 and 72 h, cells were lysed in RIPA 
buffer supplemented with 1/100 protease inhibitor cocktail (Sigma) 
for 20 min at 4°C. Lysates were centrifuged at 13000 rpm for 10 
min at 4°C and protein content in the supernatant was measured 
using the Bradford method (BioRad). Proteins were separated by 
SDS-PAGE and transferred to nitrocellulose membranes (Hybond-C 
Super; Amersham Pharmacia, UK). Membranes were blocked in Tris- 
buffered saline containing 1% Tween-20 (TBS-T)/2% BSA for 1 h, 
washed 3 times for 10 min each with TBS-T at room temperature 
and incubated overnight at room temperature with anti-V5 mouse 
monoclonal antibody (Invitrogen) diluted 1:2500 in TBS-T/2% BSA. 
Apoptosis was analyzed in HEK-293T, A549, and NCI-H520 cells 
transiently transfected as described above, hybridized in Western 
blots overnight at room temperature with anti-human poly(ADP- 
ribose) polymerase (PARP) purified mouse monoclonal antibody (BD 
Biosciences) diluted 0.5 mg/ml in TBS-T/2% BSA. Blots were 
washed with TBS-T and incubated for 1 h with secondary antibody 
(sheep ECL anti-mouse IgG, peroxidase-linked species-specific 
whole antibody; Amersham Biosciences) diluted 1:4000 in TBS- 
T/2%  BSA. After washing, blots were developed using ECL Plus 
(Amersham Biosciences).
2 .5 .6 Im m unofluorescence microscopy
HEK-293T cells grown on 13-mm coverslips were transiently 
transfected with calcium phosphate, washed in PBS, and fixed in 4%  
paraformaldehyde for 5-10 min. After several washes in PBS, cells 
were permeabilized by incubation in 1% BSA, 0.2% Triton X-100 in 
PBS for 30 min, and incubated in 10% anti-goat serum for 30 min 
followed by anti-V5 mouse monoclonal antibody (Invitrogen) diluted 
1:150. Cells were washed several times with PBS-0.2% Triton X- 
100, incubated with secondary antibody (Alexa Fluor 488 conjugate;
DCambrex) diluted 1:250, washed again in PBS-0.2% Triton X-100, 
and coverlips were mounted with Vectashield mounting medium 
including DAPI (DBA Italia). Fluorescent cells were detected using a
D Nikon Eclipse E1000 fluorescence microscope and photographed 
with a DXml200F digital camera.
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The first aim of this project was to discover and to test new 
polymorphisms (both SSLPs and SNPs) in the Pasl locus region, 
around Kras2 gene, in a population of 29 laboratory mouse inbred 
strains with known susceptibility to lung carcinogenesis. We 
detected a shared A/J- and C57BL/6J-type haplotype containing 
genomic as well as coding polymorphisms in six genes, supporting 
the hypothesis that Pasl is a multigene locus.
3.1 Pasl CONTAINING REGION
3.1 .1  Physical delim itation of the Pasl locus
Identification of Pasl candidate genes by positional cloning requires 
the reduction of the mapping region to a manageable size. After the 
first mapping studies that placed the Pasl locus in a 10-20 cM 
interval (Gariboldi eta l.,  1993), linkage disequilibrium (LD) analysis 
in mouse inbred strains of known susceptibility/resistance to 
urethane-induced lung tumorigenesis placed the Pasl locus in a 
~1.5-Mb region (Manenti eta l.,  1999).
In order to further shorten the region containing the Pasl locus we 
analyzed the (CxB)RI 5 mouse line. We decided to include this line 
for our analysis because, although this line has inherited a large 
segment of the telomeric portion of chromosome 6 from the 
susceptible BALB/c parental strain, it is however highly resistant to 
lung tumorigenesis developing 0.07 tumors per mouse after 
urethane treatment (Malkinson and Beer, 1984). This discrepancy 
was explained by the finding that the (CxB)RI 5 mouse carries the 
Kras2 allele from the resistant C57BL/6J parent line indicating the 
presence of small recombination that replaced the Pasl susceptible
3allele (from BALB/c) with the Pasl resistant allele (from C57BL/6J). 
Therefore, in this mouse line the extension of C57BL/6J inherited 
region around the Kras2 gene would be compatible with the physical 
map of Pasl.
We carried out an extensive genotype analysis of this RI line 
genotyping 45 markers on chromosome 6 (Tab.3) and we localized 
the centromeric point of recombination between markers D6Mitl98  
and D 6In tl52  (a SSLP mapping at 142.931580 Mb). The telomeric 
end of recombination was localized in a 9.9-kb fragment between 
markers D 6Int47  (145.814802 Mb) and D6Int56 (145.824723). 
D6Int47  is located in the middle of exon 4 of the Lmna-rsl gene, 
whereas D6Int56 is located in the intronic region between exons 2 
and 3 of the same gene.
This finding enabled us to further narrow the Pasl region to 468 kb. 
(Fig. 5)
Five known genes map in this 468-kb region: the branched-chain 
aminotransferase cytosolic 1 (B c a tl), the lymphoid-restricted 
membrane protein (Lrmp), the unnamed 4930469P12Rik gene that 
encodes a growth hormone-inducible soluble protein (AF412299) 
with no known protein domains, (the gene was provisionally named 
Ghiso: growth hormone-inducible soluble protein), the transforming 
protein p21 (Kras2) and the unnamed 4933403M22Rik gene that 
encodes a protein containing an intermediate filament tail domain 
related to lamin A. Therefore, the 4933403M22Rik gene was 
provisionally named Lmna-rsl (lamin A-related sequence 1). (Fig. 
5).
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C  x  B  l i n e
M a r k e r 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3
D 6 M i t 8 6 C B c * c B B C c c B * B
D 6 M i t l 3 8 C B c B c B B C c c B B B
D 6 M i t 8 3 c C c B c B B B c c B B B
D 6 M i t l c C c B c B B B c c B B B
D 6 M i t 5 0 c c c B c B B B c c B B B
D 6 M i t 2 2 3 B B c B c C C B c B B B B
D 6 M i t l 6 6 c B c B c B B C c c B C B
D 6 M i t l 5 9 c B c B c B B B c c B B B
D 6 M i t 2 6 8 B B c C c C C C c c B B B
D 6 M i t 7 4 B B c B c C c B c B B B B
D 6 M i t 2 7 4 B B c B c c c B c B B B B
D 6 M i t l 8 4 B B c B c c c C B B B B B
D 6 M i t 3 1 6 B B c C c c c B B B B B B
D 6 M i t l 0 2 C B c C c B c C c B C B B
D 6 M i t 5 4 C B c c c B c C c C c B B
D 6 M i t 2 5 B B c c c B c c c c C C
D 6 M i t l 9 8 B B c c c B c B c C c B C
D 6 I n t 2 4 C c c B C B C c C c B C
D 6 I n t 2 8 c B c B
D 6 I n t 2 6 B
D 6 I n t 2 7 B
D 6 I n t l 8 B
D 6 I n t 2 8 B
D 6 I n t 2 9 C c c B c B c c c c B C
D 6 I n t 3 c c c B c B c c c c B c
D 6 I n t 3 1 c c c B c B c c c c B c
D 6 I n t 6 c c c B c B c c c c B c
D 6 I n t 3 6 c c c B c B c c c B c
D 6 I n t 9 c c c B c B c c c c B c
D 6 M i t 5 7 B c c c B c B c c c B c
K r a s 2 _ M A L K I N S O N B c c c B c B
K r a s 2 _ 3 7 b p B c c c B c B c c c c B c
D 6 M i t l 4 B c c c B c B c c c c B c
D 6 I n t l 4 c c c B c B c c c c B c
D 6 I n t 4 6 c c c B c B c c c c B c
D 6 I n t 4 7 c c c B c B c c c c B c
D 6 I n t 5 6 c C B
D 6 I n t l 5 3 c C B
D 6 I n t 4 8 c c c c c B c c c c B c
D 6 I n t l 5 c c c c c B c c c c B c
D 6 M i t 2 9 4 B c c c c B c c c c B c
D 6 M i t 2 0 1 B c c c c c B c c c c B c
D 6 M i t l 5 B c c c c c B c c c c B c
D 6 M i t 2 6 B c c c c c B c c c c B c
D 6 M i t 3 7 2 B c B c c c B c c c c B c
Table 3 Single nucleotide polymorphism used for the analysis of (CxB)RI 
line (the lines are indicated on the top of the figure). On the left are listed 
the markers used in this study. The centromeric point of recombination is 
located between markers D6Mitl98 (in green) and D 6In tl52  (an SSLP not 
shown), while the telomeric end of recombination is located in a 9.9kb 
fragnment between markers D 6In tl47  and D6Int56 (in yellow). B is for 
Balb/c, C is for C57/BL6J
Using different programs to identify coding regions in the genome 
(NIX analysis package), we identified and then cloned a previously
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uncharacterized gene mapping between Lrmp and Ghiso. This gene 
is the mouse homolog of the human AK001783 transcript and 
corresponds to the recently identified Las l gene (Zhang et a!., 
2003) except for an additional 70 bp in the 5'-UTR. This new gene 
has 16 exons, spans a 36-kb region, and is flanked at its 3'-end by 
the 3'-end of Lrmp and at its 5'-end by the 5'-end of Ghiso. 
Subsequent LD analysis of outbred mouse lines susceptible and 
resistant to both inflammatory response and lung tumorigenesis 
delineated a 0.45-Mb region around the Kras2 gene, included in the 
previous 1.5-Mb region (Maria eta l. ,  2003).
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Figure 5 Physical map of distal Chromosome 6 and delimitation of the 
Pasl core haplotype. The upper line shows the genomic region from 
145.027489 to 146.035280 Mb, and the point of genetic recombination in 
the mouse CXB5 RI line (black and hatched boxes indicate the C57BL/6J- 
and BALB/c- derived chromosomes, respectively). The genotyping of 65 
genetic markers in this 1 Mb region identified a core Pasl haplotype, 
between D6Int24 and D6Int47, which contained 54 of these markers and 
the six genes shown. The approximate locations of the genes are depicted 
above (sense) and below (reverse) the segment representing the DNA 
sequence of that region. Introns are depicted by lines, the exons are 
depicted by solid vertical bars. Positions of the alignments are based on 
the Ensembl database. (Lasl is for Cascl)
We performed a nucleotide sequence analysis of genomic fragments 
for a total of 20000 bp in the Pasl region and this allowed us to
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iid e n t i fy  159 SNPs/SSLPs (T a b .4). A m ong the se  m a rk e rs ,  we 
analyzed 27 SSLP and 37 SNP (see T a b .6 and T a b .7 fo r  m ore 
details) between A/J and C57BL/6J mice selected according to th e ir  
pos ition and the  d is tance  be tw een each o the r. We s ta r ted  ou r 
analysis ge no typ ing  these selected m arkers  in 24 m ouse inbred 
s tra ins  w ith  known suscep tib i l i ty  to  lung carc inogenes is  (T a b .5). 
Some SNP m arkers were analyzed in 89 inbred s tra ins w ith  known 
susceptib il i ty  to lung carcinogenesis fo r  a m ore com p le te  analysis 
(see Fig.6 fo r ASO hybrid ization example).
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Marker Gene Type PCR 
Primers Name
Detection
method
SNP
Polymorphism
Amino-acid
change
D6lntl52 SSLP CCTCTAGCCTCCTTGGGAAC
TTCTGTCCTTTGGGGAAGG
D6Mit114 SSLP TGCAGAGACTCACAATTCACG
AGGCCCTGTGCTGGCTAAG Agar 145022
D6lnt20 SSLP TGCAGAGACTCACAATTCACG
AGGCCCTGTGCTGGCTAAG 32P 1
D6lnt16 SSLP TGGGCCATGCTACAAGTTCTCCATGTTTGCTCTTGTGCTG agar |
D6lnt21 SSLP
TGGAGTGCTCTGAGCTGTTG
CCTATCTGTCAGTTTTATCCCTTGT agar
|
D6lnt22 SSLP TCTGTACCTAGGGGCTGTGAA
CACACCTGCATACAAGCACA agar
D6lnt23 SSLP
GGAAGTAACTTGTGCCAGGATT
TGCCCTAGGGAGTGTCTTATG 32P !
D6lntl7 SSLP CAATGCGGGTTTATCTGTCA
TACATGCACGACCCTCACAT agar
D6lnt2 4 SSLP
GGGAAATTGGTGGGAAGAAG
CCTTGACTTTTGTTTCCTACCC agar
D6lnt25 SSLP TGTCTAACTTCCCAGACCAACACAAAGTGGCAGTGTCCTCAA agar
D6lnt26 SSLP GGCATCTCATTCCTTCTTTCA
CTGCTTGAATGCTTGGGTTT agar ------------
D6lnt27 SSLP TGCATTCGTGTGCACATTC
GTGCCCTTACCCACTGTCAT agar
D6lnt18 SSLP
ATCCCACAACCTCATTCCAA
CCTCCATTCTGTATGGCAAGA 32P
D6lnt28 SSLP TGCTCACTGGCAACATGAACGAGGCTCTCTCATGGCCTTT agar
D6lntl9 SSLP GGCCCATCCAGTCTTAGGTT
CAGGTTGGCTTGGCTTATCT 32P
D6lnt29 SSLP
CCCTGATACCACACATGCAC
CTAGCTGGGCCAAGAAAGC 32P
D6lnt30 SNP GGGAGACAAACACACCTGCTGCAAGTGGATGCTAGGAACAG TTTTACA[C/T]TGAAACC Genomic
D6lnt3 SSLP
GCCATCTCAGTGGAGGCTTT 
CAT GT CAGAGAT GAGC T GT GC 33P
D6lnt31 SSLP
AAACACGATATAGGCCCATTTAATA
GTTGCTTTTCTTGGGCTGGT 33P
D6lnt53 Lrmp_Exl SNP
TGGCACCCTCTTGTCACGT
CCCATGCTCTGTGTAAA GTAAAAG(G/A]TCCCCCA G -> N
D6lnt4 Lrmp_Ex2 SNP ttt tgca g a a a g c c a c t c t t t
TCCTAGGACGCCCCATACTA ACGGAAG(G/A]CTCCATC G -> D
D6lnt5 SSLP TGAGCAGTCTCTCCAACCTCA
TCTGCCAGTACCCACGTACA 33P
D6lnt32a Lrmp_Ex3 SNP TACGTGCCTAAAGCGACCTT
TTTGTTCCCACTGGCTTTTC GGTGCTG[A/G]CCACTT[G/C]TATTC(C/TJTGTACCA D -> G
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D6lnt32b Lrmp_Ex3 SNP
TACGTGCCTAAAGCGACCTT
TTTGTTCCCACTGGCTTTTC GGTGCTG (A/G ] CCACTT [ O/C] TATTC (C/T ] TGTACCA
[
L -> F
D6lnt32c Lrmp_Ex3 SNP
TACGTGCCTAAAGCGACCTT
TTTGTTCCCACTGGCTTTTC GGTGCTG[A/G]CCACTT(G/C]TATTC[C/TJ TGTACCA S -> S
D6lnt3 3 SNP TACGTGCCTAAAGCGACCTT
TTTGTTCCCACTGGCTTTTC CGAGAGG[T/C]GGCGCCC Intronic
D6lnt34
SSLP
20bp_ins
GGTGGAATGCCTTGATCATT
AGGAGCTGAGCTGCAGAAAG
|
D6lnt58 Lrmp_Ex6 SNP
AAATTCAGAGGGACAGATCCTACA
GCTGCTTCTTCCTCTTTTGATTG agar T(A,B6/C(CBA)
I
CODING
| D6lnt35 SSLP
TCTTCCTGGCTCTGATGACC
GGGCAATATTGGCTAAATATAAATCA 33P !
D6lnt59 Lnnp_Exll SNP
TC [ G/A]
s  - >  s
D6lnt60 Lrmp_Exll SNP
AT(C(a=b6/A(cba)J
I -> I
D6lnt6 SSLP
TCCAAAATGGCCCTGCTTAT
GTTGCCCTCTGACTTCCACA 33P
D6lnt61 Lrnip_Exl3 SNP AAJG/A] K -> K
D6lnt3 6 SSLP
GGGTGCTGTTGCTTAGTGGT
ACACGTTTGTGGTGGTGTGA 33P
D6lnt54 Lrnip_Exl7 SNP
GTGGGTCTCACCTGACCATT
CCTGCCCTCAGTAAGCACA AGTGGAG [ G/A J GGACCAG
G 438 R
D6lnt7 Lrmp_Exll INS SSLP GTGGGTCTCACCTGACCATT
CCTGCCCTCAGTAAGCACA agar
STL ->STLSTL
D6lnt62 Lrmp_Ex18 SNP GC [ C {A, B6) /G(CBA) ] A -> A
D6lnt8 Lrmp_Exl8 SNP
GAGCTTCCTCACAGGTCAGC
TGCTGAGGACCCTAGCTTTG GGACCAC[T/C]GCCAGTG L 537 P
D6lntl41 Cascl_Ex16 SNP
GGACCCCACCTAGGGTATTT
GCAATCCCAGAATTCACGTT CCTCCCC [ C / G1 GTGGCAA P 700 P
D6lnt154 Cascl Ex 16 SNP
GGACCCCACCTAGGGTATTT
GCAATCCCAGAATTCACGTT AGGGCAC [ C / G ] GAGTTCC T 684 T
D6lnt63 |
D6lnt64 CasclJEx16 SNP GGACCCCACCTAGGGTATTT
GCAATCCCAGAATTCACGTT GAAGAAA[C/T]AGAGCAC
T 649 I
D6lnt65 Cascl_ExlSg SNP
CCACACAGACACTCCCACAC
CCTTGAAACGAACCCTTCTG CCTTCTC [ G/C J GGTGTTT Intronic
D6lnt37a CasclJEx14g SNP
GACAATGCACAGCAGTGACG
CCAGAGGGAGCTTGGAAAGT AAGAAGA[G/T JAAAGGAA Intronic
D6lnt37b Cascl_Exl4g SNP
GACAATGCACAGCAGTGACG
CCAGAGGGAGCTTGGAAAGT TCTTGGG[A/C]CTCTTCT
Intronic
D6lnt66 Cascl_Exl3q SNP
CTGGGGACACACTGCCTAAC
GGCTAATAGGCGCCTGAAAT CCTAACT[A/GJTGGGCGG Intronic
D6lnt67 CasclJExl3 SNP CTGGGGACACACTGCCTAACGGCTAATAGGCGCCTGAAAT ACCTTCA [ G/A J TATGGAT S 498 N
D6lnt68 Cascl_Exl2g SNP
TGCAGTTGTTTGCACTACCC
CGCAGGAAGGTCTGAGGTTA C/T Intronic
D6lnt69 CasclJExl2g SNP
TGCAGTTGTTTGCACTACCC
CGCAGGAAGGTCTGAGGTTA C/O
Intronic
D6lnt7 0 Cascl_Exllg SNP GGCTGTATCAAGGGCTGACTTATCCTTCTTGACCGCAACA C/T Intronic
D6lnt71 CascI_Exllg SNP
GGCTGTATCAAGGGCTGACT
TATCCTTCTTGACCGCAACA A/G
Intronic
D6lnt72 Cascl_Exllg SNP
GGCTGTATCAAGGGCTGACT
TATCCTTCTTGACCGCAACA A/G
Intronic
D6Int7 3 CascI_Exllg SNP GGCTGTATCAAGGGCTGACTTATCCTTCTTGACCGCAACA G/A Intronic
D6lnt7 4 Cascl_Exllg SNP
GGCTGTATCAAGGGCTGACT
TATCCTTCTTGACCGCAACA G/A
Intronic
D6lnt7 5 Cascl_Ex11 SNP
GGCTGTATCAAGGGCTGACT
TATCCTTCTTGACCGCAACA CACAGCIT/AJG[T/C]GCCTGG
C -> R
D6lnt76 CasclJExll SNP
GGCTGTATCAAGGGCTGACT
TATCCTTCTTGACCGCAACA CACAGC(T/AJG|T/C]GCCTGG L -> Q
D6lnt77 Cascl_Ex12 SNP
GGCTGTATCAAGGGCTGACT
TATCCTTCTTGACCGCAACA C/T
Intronic
D6lnt7 8 Cascl_ExlOg SNP ATGAGGCAGGTTACCAATGC
TACGGACCAATACCCTCCTG C/T
Intronic
D6lnt79 Cascl_Ex9g SNP
GCCAGCTTGGGCTACCTATC
GGGGCATTAAAAAGGACACC G/A
Intronic
D6lnt80 Cascl_Ex9 SNP GCCAGCTTGGGCTACCTATCGGGGCATTAAAAAGGACACC AAAAG|C/TJ TCTTTACT L -> F
D6lnt81 Cascl_Ex9 SNP
GCCAGCTTGGGCTACCTATC
GGGGCATTAAAAAGGACACC AAGGCC[A/O]TGACTGAA
M -> V
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D6lnt38 Cascl_Ex9 SNP
GCCAGCTTGGGCTACCTATC
GGGGCATTAAAAAGGACACC GAGCAAAA[T/A] CA(G/A]AACCCC
i
Q 278 Q
D6lnt82 Cascl_Ex9 SNP GCCAGCTTGGGCTACCTATC
GGGGCATTAAAAAGGACACC GAGCAAAA[T/A]CAIG/A ]AACCCC N -> K
D6lnt83 Cascl_Ex9 SNP
GCCAGCTTGGGCTACCTATC
GGGGCATTAAAAAGGACACC ATTGCT(C/T]GTGGCCAG T -> T 1
D6lnt84 Cascl_Ex8g SNP
GCCAGCTTGGGCTACCTATC
GGGGCATTAAAAAGGACACC C/T Intronic
D6lnt85 Cascl_Ex8g SNP GCACGCCTGCTCTAGACACT
CCAGCTTCCTCCAGGAGTTC T/G
|
Intronic
D6lnt39 Cascl_Ex6g SNP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG A/T Intronic
D6lnt86 Cascl_Ex6g SNP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG G/A Intronic
D6lnt87 Cascl_Ex6g SNP CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG G/A Intronic
D6lnt88 Cascl_Ex6g SSLP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG agar 5bp Del Intronic
D6lnt89 Cascl_Ex6g SNP CACTCACCAGACAGCAGCACTGGTGGAAGGAGTGAAATGG G/A Intronic
D6lnt90 Cascl_Ex6g SNP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG A/G
Intronic
D6lnt91 CascI_Ex6g SNP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG T/G Intronic
D6lnt92 Cascl_Ex6g SNP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG G/T Intronic
D6lnt93 Cascl_Ex6g SNP CACTCACCAGACAGCAGCACTGGTGGAAGGAGTGAAATGG G/A Intronic
D6lnt94 Cascl_Ex6g SNP
CACTCACCAGACAGCAGCAC
TGGTGGAAGGAGTGAAATGG T/G Intronic
D6lnt40 Cascl_Ex6g SNP
ATCTCACCAGCCTGGAGCTT
TTAATTCCTGCAGCCACCAC C/T Intronic
D6lnt9S Cascl_ExSg SNP ATCTCACCAGCCTGGAGCTTTTAATTCCTGCAGCCACCAC C/A Intronic
D6lnt96 CascI_Ex5g SNP
ATCTCACCAGCCTGGAGCTT
TTAATTCCTGCAGCCACCAC A/C Intronic
D6lnt97 Cascl_Ex4g SNP
AAACCCAAGCAAACAGACCA
GCAAAAGGATGCCTTCGACAA T/C Intronic
D6lnt98 CascI_Ex4g SNP
AAACCCAAGCAAACAGACCA
GCAAAAGGATGCCTTCGACAA T/C Intronic
D6lnt99 Cascl_Ex4g SNP AAACCCAAGCAAACAGACCAGCAAAAGGATGCCTTCGACAA A/T Intronic
D6lnt100 Cascl_Ex4g SNP AAACCCAAGCAAACAGACCA
GCAAAAGGATGCCTTCGACAA C/T Intronic
D6lnt41 Cascl_Ex4 SNP
AAACCCAAGCAAACAGACCA
GCAAAAGGATGCCTTCGACAA AAGTGGA[G/A]TCTGCTG S -> N
D6lnt101 Cascl_Ex4 SNP
AAACCCAAGCAAACAGACCA
GCAAAAGGATGCCTTCGACAA T/C Intronic
D6lnt102 Cascl_Ex4 SNP AAACCCAAGCAAACAGACCA
GCAAAAGGATGCCTTCGACAA A/G Intronic
D6lntl03 Cascl_Ex3 SNP
AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT G/A Intronic 
5 ‘UTRD6lntl04 Cascl_Ex3 SNP
AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT G/T
D6lntl05 Cascl_Ex3 SNP AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT A/T 5 'UTR
D6lntl06 Cascl_Ex3 SNP
AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT G/A 5 'UTR
D6lntl07 Cascl_Ex3 SNP
AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT T/C 5 UTR 
5 'UTRD6lntl08 Cascl_Ex3 SNP
AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT T/C
D6lntl09 Cascl_Ex3 SNP
AAACATGGGCTGATCACCTG
ATCCTAGTGCAGGCCTGTGT T/G 5 'UTR
D6lnt9 Cascl_Ex2 SSLP
GGGAACCAGGTCCTCTTCAA
GACCAGAATGCTGGACATGG 33P
D6lntll0 SEQ
CAGAGC CAAAGT GGGAAT GT 
AGCTCTTGAGAAGGGCGAAT sequence ]
D6lntll1 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence 1
D6lntll2 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntll3 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntll4 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence |
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D6lnt115
I
SEQ CAGAGCCAAAGTGGGAATGTAGCTCTTGAGAAGGGCGAAT sequence
D6lntl16 SEQ CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntll7 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntl18 SEQ CAGAGCCAAAGTGGGAATGTAGCTCTTGAGAAGGGCGAAT sequence
D6lntl19 SEQ CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntl20 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lnt121 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntl23 SEQ CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntl24 SEQ
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT sequence
D6lntl25 SEQ CAGAGCCAAAGTGGGAATGTAGCTCTTGAGAAGGGCGAAT sequence
D6lnt44 GhisoJExl SNP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT A/T
5 UTR
D6lntl26 Ghiso_Exl SNP TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT T/C
5 UTR
D6lntl27 Ghiso_Exl SNP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT T/A
5 UTR
D6lnt128 GhisoJExl SNP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT C/G Intronic
D6lnt129 Ghiso_Exl SSLP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT 32P 5 bp Ins
Intronic
D6lntl30 GiisoExl SNP
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT
D6lntl31 Gbiso_Ex2 SNP
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT
D6lntl32 Ghiso_Ex2 SSLP CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT 32P
D6lnt13 3 Ghiso_Ex2 SNP
CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT
D6lntl3 4 Ghiso_Ex2 SNP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT C/T Intronic
D6lnt135 Ghiso_Ex2 SNP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT
D6lntl36 Ghiso_Ex2 SNP CAGAGCCAAAGTGGGAATGT
AGCTCTTGAGAAGGGCGAAT
D6lnt137 Ghiso_Ex2 SNP
TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT T/G Intronic
D6lnt42 Ghiso_Ex3 SNP
GGCCAATTCGTTACGAGGA 
C GATAGTGACAAT C T CATCAGTAAAT G T/C Intronic
D6lntl0 Ghiso_Ex3 SNP
TTTTTAAAGCTGCTGTATCTTGGA
CAAGGCCTCTAGCTCCTTCA GGAGCAG[A/G]CTATTTT
D -> G
D6lnt11 Ghiso_Ex3 SSLP
TGACTGCATAATTCTCAATAAATCACT
TTCATCTCATTTTGTATTCCACTGA 33P
D6lntl3 8 Kras2_lB SNP
TGTCCATCTACTCATCCAA
GAGGGAGTGACCAAGATTA G/A 3 ' UTR
D6lntl39 Kras2_4B SNP TGTCCATCTACTCATCCAA
GAGGGAGTGACCAAGATTA C/A
3 ' UTR
D6Mit57 Kras2 Ex 1 SSLP
TCTGATATCCAAGTCATCGTGG
AAACCAAACAAAAGGAGTGGC agar
D6lnt140 Kras2_494 SNP Kras2_494
1
Kras2_21 Kras2 Ex 1 SSLP
GCCTCACCGAAAGACAGATCA
AATCAAAGGAGCTGGGAACA agar
............... i
06lnt142 Kras2 Ex 1 SNP
AAGCGCACGCAGACTGTAG
GGCTGTTTAGATCAACAAGCTAAAT
Kras2 Ex 1
............... j
D6lnt143 Kras2_Exlg SNP
AAGCGCACGCAGACTGTAG
GGCTGTTTAGATCAACAAGCTAAAT
D6lnt144 Kras2_Exlg SNP
AAGCGCACGCAGACTGTAG
GGCTGTTTAGATCAACAAGCTAAAT
i
D6lnt145 Kras2_Exlg SNP
AAGCGCACGCAGACTGTAG
GGCTGTTTAGATCAACAAGCTAAAT
D6lnt12 RS25_Intron SSLP
TTCCAGACTTGCAAAGCAAA
CTGAGGGAGCTCTGTGAAGG 33P
D6lnt43 SNP_157517_end_BAC SNP
TCTCAATCTCACGCACCATC
ttc cccc a c a c t g a c t g t a g g
C/T Genomic
ft
ft
f t
f t
ft
f t
D6lntl46 S NP_157 56 3_end_BAC SNP TCTCAATCTCACGCACCATCTTCCCCCACACTGACTGTAGG T/C Genomic j
D6lnt14 Lmna-rs1_Ex 8 SSLP ACCAAGTAAGTTCCAGGACAGC
AGACAAATCATCTGCCTTGTGG agar
Genomic 1
D6lnt46 Lmna-rsl_Ex5 SNP
ACAGCCACCAACGGACTTT
CATTGGGCTTGCACAAGAT TGGGAGG[A/G]ACAGAGC
E -> G j
D6lnt47 Lmna-rsl_Exl SNP ATGTTGTCGGGGAACTGGTAAGATTCCAAACACGCACCTC AATGGACIA/G]CGCAGTC H -> S j
D6lnt147 Lmna-rsl_Ex4 SNP ATGTTGTCGGGGAACTGGTA
AGATTCCAAACACGCACCTC j
D6lntl48 Lmna-rsl_Exi SNP
ATGTTGTCGGGGAACTGGTA
AGATTCCAAACACGCACCTC j
D6lnt149 Lmna-rslJExi SNP ATGTTGTCGGGGAACTGGTAAGATTCCAAACACGCACCTC |
D6lnt56 Lmna-rsl_Ex2 SNP TAGGGACTCACGGCAAGTTTGCACTCAGATGCCTTGCTTT CxB)RI 5 Allele Balb
|
D6lntl53 Lmna-rsl_Exl SNP
AGCTCCTTCCATGACAGAGG
CGAGGTCGTTGGTTGTCATA C/T
it48 Lmna-rsl 5'genomic SSLP
ATCTCCAGGGAACTGCTTCA
AGCATACCTGGGCATACAGC 32P
i
D6lntl5 Lmna-rsl 5'genomic SSLP
TTGCATGCAGACACACACAA
GTCAAATGGACACGTGGAAA 32P
|
D6lnt49 SSLP CCTTGAGTTTGTGGCTCTCC
AGGCCATGTGCAGTACCTTC 32P |
D6lnt50 SSLP GGGCAGCATAGCAAGTTTCA
GCCAAGGTGAGGTTTTGAGA 32P j
D6lnt51 SSLP CCAGAACTGGTGCTGCTTTTATCTCCAGGGAACTGCTTCA 32P |
D6lnt52 SSLP TCGTGTCAAGCCACTTAGTCA
TTGCATGCAGACACACACAA 32P |
D6Mit14 SSLP
ATGCAGAAACATGAGTGGGG
CACAAGGCCTGATGACCTCT 32P
|
D6lnt57 SSLP
AGGTTCTGCAAACTCCTCCA
TGTCCCCTGAACCCATGTAT 32P
|
D6lnt45 SSLP ACAGGCCCAGCTCAAGATTT
ACCCAGGTCAGGTAGCCTCT 32P
j
D6lnt55 END YAC Y95M5E3 SNP GGCTCCTGGTGGTTTGTCAA
TTGCAACTCTCTGCTGGACT A/G
|
D6lnt150 END YAC Y95M1F5 SNP
GGATGTGTGGTAATCGGAAGA
CAAAGACACTTGCCACTAAGC A/G
D6lntl51 END YAC Y88M6a6 SNP
GATCAACATCTGTCGGGAAGA
TCTGGAGGTTGTGGTACCCA T/G
D6lntl3 SSLP CAAGCACACACACTTACAACCA
TCATGGAGGCCTATAAGCAGA j
Table 4 159 SNPs/SSLPs identified in the nucleotide sequence analysis of 
genomic fragments for a total of 20000 bp in the Pasl region.
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0Susceptibility Strain
Haplotype
type
Reference
Manenti G., 2002
D
Susceptible A/J A/J Malkinson A .M .,1983
Falconer D.S.,1962
SWR/J A/J Manenti G.,1997 
Malkinson A.M.,1983
FVB/NJ A/J Shafarenko M.,1997 
Mahler J.F., 1996
STS/A A/J Van der valk M.A. 1981
0 In te rm ed ia te CBA A/J Ryan J., 1987 
Maltoni C., 1989 
Manenti G., 1997
BALB/CJ A/J Malkinson A.M.,1983 
Trainin N., 1964
129/SvJ A/J Malkinson A.M.,1983
O RF/J A/J
Ryan J., 1987 
Maltoni C., 1989
PL/J A/J Malkinson A.M.,1989
LP/J A/J Smith G.S., 1973
ST/Bj A/J Malkinson A.M.,1989
D MA/MyJ A/J Hoag W.G., 1963
Resistant P/J C57BL/6 Hoag W.G., 1963
SM/J C57BL/6 Malkinson A.M.,1989
o
AKR/J C57BL/6 Malkinson A.M.,1983 
Malkinson A.M.,1989
C58/J C57BL76 Thaete L.G., 1991
DBA/1J C57BL/6 Trainin IM., 1964
DBA/2J C57BL/6 Smith G.S., 1973 
Malkinson A.M.,1983
0 C57L7J C57BI76 Malkinson A.M.,1983
C3H/HeJ C57BL76 Malkinson A.M.,1983 
Hoag W.G., 1963
C57BL/6J C57BL/6 Malkinson A.M.,1983  
Malkinson A.M.,1989
C57BL/10J C57BI76 Malkinson A.M.,1983
0 SJL/J C57BL76 Malkinson A.M.,1989
C57BR/cdJ C57BL/6 Malkinson A.M.,1983
Table 5 Inherited predisposition to lung tumorigenesis in 24 mouse inbred 
O strains.
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A-type polymorphism G-type polymorphism
Figure 6 Example of detection of a SNP polymorphism (D6IntlO) by allele- 
specific oligonucleotide (ASO) hybridization in 86 inbred strains. DNA 
samples were amplified by PCR, blotted on nylon membranes, and 
hybridized with either a radiolabeled A-type oligonucleotide (on left) or a 
radiolabeled G-type oligonucleotide (on right). The mouse strains studied 
in my thesis are in red. C l:  129/SvJ; E l: A/J; FI: AKR/J; A2: Balb/CJ; D2: 
C3H/HeJ; F2: C57BL/10J; H2 C57BL/6J; A3: C57L/J; B3: C57BR/cdJ; D3: 
C58/J; A4: CBA; B4: CE/J; D4: DBA1/J; E4: DBA2/J; G4: FVB/NJ; E5: 
LP7J; F5: MA/MyJ; H6: NZB/B1NJ; C7: P/J; G7: PL/J; B8: RF/J; C8: 
RIIIS/J; B9: SJL/J; E9: SM/J; H9: ST/BJ; BIO: SWR/J; A l l :  NGP/N; B l l :  
STS/A; D l l :  O20/A.
Subsequently, a Medline search was conducted to increase the
»
number of strains. We decided to include five new strains of known 
susceptibility to lung cancer. In particular, NGP/N (Malkinson, 1989) 
and O 20/A (B en tve lzen , 1966) are suscep tib le  to  lung 
tum origenes is , R IIIS /J  express in te rm ed ia te  s u sce p tib ility  
(Malkinson and Beer, 1983; Falconer and Bloom, 1962) while 
NZB/B1NJ (Malkinson and Beer, 1983) and CE/J (Festing and 
Blackmore, 1971) are resistant.
»
»
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Position (kb) Marker Gene PCR primers
142931483 D6Intl52 CCTCTAGCCTCCTTGGGAAC
TTCTGTCCTTTGGGGAAGG
145027489 D6Int20 TGCAGAGACTCACAATTCACG
AGGCCCTGTGCTGGCTAAG
145175879 D6Intl6 TGGGCCATGCTACAAGTTCT
CCATGTTTGCTCTTGTGCTG
145230814 D6M21 TGGAGTGCTCTGAGCTGTTG
CCTATCTGTCAGTTTTATCCCTTGT
145337579 D6Intl7 CAATGCGGGTTTATCTGTCA
TACATGCACGACCCTCACAT
145346401 D6Inl24 GGGAAATTGGTGGGAAGAAG  
CCTT G ACTTTTGTTTCCT ACCC
145363293 D6Int25 T GTCTA ACTT CCC AG ACC A AC A 
CAAAGTGGCAGTGTCCTCAA
145389499 D6Inl26 GGCATCTCATTCCTTCTTTCA
CTGCTTGAATGCTTGGGTTT
14539S672 D6Inl27 TGCATTCGTGTGCACATTC
GTGCCCTTACCCACTGTCAT
145403158 D6IntlS ATCCCACAACCTCATTCCAA
CCTCCATTCTGTATGGCAAGA
145434169 D6Int29 CCCTGATACCACACATGCAC
CTAGCTGGGCCAAGAAAGC
145506667 D6Int3 Lrmp GCCATCTCAGTGGAGGCTTT
CATGTCAGAGATGAGCTGTGC
145520113 D6Int31 Lrmp A A ACACGATATAGGCCCATTT A ATA  
G T TG C TT U  C 1 1GGGCTGGT
145532679 D6Int5 Lrmp TGAGCAGTCTCTCCAACCTCA
TCTGCCAGTACCCACGTACA
145556176 D6Int6 Lrmp T  CCA AA AT GGCCCT GCTT AT  
GTTGCCCTCTGACTTCCACA
145559317 D61nt36 Lrmp GGGTGCTGTTGCTTAGTGGT
ACACGTTTGTGGTGGTGTGA
145595636 D6Int9 Lasl GGGAACCAGGTCCTCTTCAA
GACCAGAATGCTGGACATGG
145599886 D6Intl29 Ghiso TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT
145599956 D6Intl32 Ghiso TCGAGTCCCATACACTGCTG
AGCTCTTGAGAAGGGCGAAT
145605994 D61ntU TGACTGCATAATTCTCAATAAATCACT  
TT  CAT CT CATTTT GTATT CC A CTG A
145634766 Kras 2^3 7 Kras2 CAGGGCTGCATAGTAAGA
GGGTGTTAGGGAACCATA
145644184 D6lntI2 TTCCAGACTTGCAAAGCAAA
CTGAGGGAGCTCTGTGAAGG
145788908 D6Intl4 ACCAAGTAAGTTCCAGGACAGC
AGACAAATCATCTGCCTTGTGG
145833516 D61nt48 ATCTCCAGGGAACTGCTTCA
AGCATACCTGGGCATACAGC
145836112 D6Intl5 TTGCATGCAGACACACACAA
GTCAAATGGACACGTGGAAA
145931230 D6Int52 GATGTGACACAGCAGGATGC
ACCATGGGATCCAGAGATCA
146035280 D6Int45 ACCCAGGTCAGGTAGCCTCT
ACAGGCCCAGCTCAAGATTT
Table 6 Simple sequence length polymorphism with PCR primers used for 
the analysis of the Pasl locus
0Position (kb) Marker Gene Exon GenBank Acc. jj- SNP polymorphism3 Amino-acid variation3
145501932 D6Int30 AY490381 C145501932T Genomic
145526703 D6Int4 Lrmp 2 AJ437328 G 145526703A G31D
145536150 D6Int32a Lrmp 3 AY490382 A145536150G D56G
145536157 D6Int32b Lrmp 3 AY490382 G 145536157C L58F
145536163 D6lnt32c Lrmp 3 AY490382 C145536163T S60S
145536417 D6Inl33 Lrmp AY490382 T145536417C Intronic
145562248 D6Int54 Lrmp 17 AJ437329 G 145562248A G438R
145563172 D6intS Lrmp 18 AJ437330 T145563172C L537P
145566018 D6Int37a Lasl AY490383 G145566018T Intronic
145580048 D6Int3S LasI 9 AY490384 C145580048T Q278Q
145580256 D6lntS4 Lasl 9 AY490384 C1455S0256T Intronic
145589112 D61nt40 Lasl 5 AY490385 C 145589112T Intronic
145589248 D6Int95 Lasl 5 AY490385 C l45589248A Intronic
145589273 D6lnt96 Lasl 5 AY490385 A145589273C Intronic
145591455 D6Int41 Lasl 4 AY490386 C145591455T S60N
145591604 D6Intl01 Lasl 4 AY4903S6 T145591604C Intronic
145591661 D6IntI02 Lasl 4 AY490386 A145591661G Intronic
145599704 D6Int44 Ghiso 1 AY490387 A145599704T 5’-UTR
145599728 D6IntI26 Ghiso 1 AY490387 T145599728C 5MJTR
145599744 D6Intl27 Ghiso 1 AY4903S7 T145599744A S’-UTR
145599847 D61ntl28 Ghiso AY490387 C145599847G Intronic
145599922 D6inll30 Ghiso AY490387 G 145599922A Intronic
145599947 D6Intl31 Ghiso AY490387 G 145599947A Intronic
145600006 D6Intl34 Ghiso AY490387 C145600006T Intronic
145600020 D61ntJ35 Ghiso AY490387 G145600020T Intronic
145600058 D 6M I37 Ghiso AY490387 T145600058G Intronic
145603833 D6M42 Ghiso AY490388 T145603833C Intronic
145603889 D6IntlO Ghiso 3 AJ437332 A145603889G D28G
145635211 D61ntl42 Kras2 1 AY490389 A1456352I1G Y32Y
145635417 D6Intl43 Kras2 AY490389 A 145635417G Intronic
145635480 D6InlM5 Kras2 AY490389 A1456354S0G Intronic
145656172 D6Inl43 AY490390 C l45656172T Genomic
145656218 D6Ini 146 AY490390 T 145656218C Genomic
145812513 D6Inl46 Lmna-rsl 5 AY490391 T145S12513C E258G
145814801 D6M47 Lmna-rsl 4 AY490392 T145814S01C H218S
145824723 D6Int56 Lmna-rsl AY490393 C145S24723T Intronic
145828658 D6M153 Lmna-rsl AY490394 C145828658T Intronic
aPolymorphic markers are labelled such that the C57BL/6J allele is followed by the position in the 
Ensembl alignment and then the A/J allele.
Genomic and intronic polymorphisms occur in intergenic and intragenic regions, respectively.
Table 7 Single nucleotide polymorphisms used for the analysis of the Pasl 
O locus
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3 .1 .2 Pasl haplotype
The 468-kb region defined a core Pasl haplotype characterized by 
two main types: an A/J and a C57BL/6J type. The boundaries of the 
core were physically defined by the decay of its association to alleles 
at <145.346 Mb (D6Int24) and at >145.815 Mb (D6Int47) from the 
chromosome 6 centromere.
In this region we analysed 54 markers, 42 (78% ) of which showed 
perfect segregation with the haplotype, that is, no strain of the A/J 
type carried a C57BI/6J- type polymorphism and vice versa. The 
perfect segregant markers included both coding and non-coding 
polymorphisms; the latter were located either in the intragenic or 
intergenic regions of six genes mapping in the haplotype. (Tab. 8)
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Table 8: Haplotype map of distal Chromosome 6 region including the Pasl 
locus. The mouse strains screened are indicated at the top of the figure, 
while the 54 genetic markers from the core Pasl haplotype region are 
listed on the left in colors to indicate molecular variations in non-coding 
regions (blue) or in coding regions (magenta, no amino acid change; red, 
amino acid change). Polymorphisms observed are shown in each cell and 
those present in A/J and in C57BL/6J are indicated in green and yellow, 
respectively. SNPs are shown as nucleotides according to the Ensembl 
database. SSLP-based polymorphisms are shown as allele numbers, whose 
values are inversely correlated with DNA fragment size. The location 
column indicates the physical position (in megabases) from the 
centromere according to the Ensembl database. The haplotype blocks and 
the markers that segregate appropriately according to the A/J- and 
C57BL/6J-type are boxed.
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3.1 .3  Coding region nucleotide polymorphism analyses
SNPs analyses revealed that all these genes, except B c a tl, showed 
nucleotides polymorphisms between A/J and C57BL/6J mice that 
produced amino acid changes (Tab.9).
Gene Marker Position
A/J
allele
C57BL6/J
allele
Amino-acid
change
Exon SNP type
Lrmp D6Int4 145526703 A G G31D 2 Non-synonymous
Lrmp D6Int32a 145536150 G A D56G 3 Non-synonymous
Lrmp D6Int32b 145536157 C G L58F 3 Non-synonymous
Lrmp D6Int32c 145536163 T C S60S 3 Synonymous
Lrmp D6Int54 145562248 A G G438R 17 Synonymous
Lrmp D6Int8 145563172 C T L537P 18 Non-synonymous
Cascl D6Int41 145591455 A G S60N 4 Non-synonymous
Cascl D6Int38 145580048 A G Q278Q 9 Synonymous
Ghiso D6IntlO 145603889 G A D28G 3 Non-synonymous
Kras2 D 6Intl42 145635211 G A No 1 Synonymous
Lmna-rsl D6Int47 145814801 A G H218S 6 Non-synonymous
Lmna-rsl D6int46 145812513 A G E258G 7 Non-synonymous
Table 9 Nucleotide polymorphism between A/J and C57BL/6J mice in Lrmp, 
Cascl, Ghiso, Kras2 and Lmna-rs gene. Coding polymorphism linked with 
the Pasl haplotype are shown in red.
Lrmp gene carries two amino acid-changing polymorphism ting ly  
linked with the Pasl haplotype: a D56G polymorphism (D6Int32a ) in 
exon 3 and a L537P polymorphism (D6Int8 ) in exon 18. In particular 
the D6Int8 polymorphism segregates with both the Pasl haplotype 
and the susceptib ility  in flam m atory response in mouse lines 
phenotypically selected fo r high and low acute in flam m ato ry  
response (Maria e t al., 2003). Additional amino acid changes 
(D6Int4  and D6Int32b ) were found, but they are not linked with the
Pasl haplotype while the D6Int32c polymorphism in exon 3 is a 
silent polymorphism. (Fig.7)
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ATG
Ex 2 Ex 3 Ex 17 Ex 18
TATTCT GAG 
TAT TCC GAG
D 6Int32C
D 6 In t4 D 6 In t8
D 6In t32a
Non-synonymous
CAC TTG TAT 
CAC TTC TAT
GCT GAC CAC 
GCT GGC CAC
GAA GGCTCC 
GAA GAC TCC
CCA CTG CCA 
CCA CCG CCA
GGA GGG GAC 
GGA GAG GAC
Non-synonymous and not linked 
Synonymous
D 6In t32b D 6 In t54
Figure 7 Amino-acid changed polymorphisms in Lrmp. The boxes indicate 
the A/J (down) and C57BL6/J (on the top) sequence.
Analysis of Cascl showed a S60N polymorphism (D6Int41 ) in exon 4 
and silent Q278Q polymorphism (D6Int38 ) in exon 9. (Fig.8)
»
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ATG
Ex 4 Ex 9
D 6 In t4 1 CAA AAC 
CAG AAC
TGG AAT CTG 
TGG AGT CTG
Non-synonymous
Synonymous
D 6 In T 3 8
Figure 8 Amino-acid changing polymorphisms in Cascl. The boxes indicate 
the A/J (down) and C57BL6/J (on the top) sequence.
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We found a polymorphism non-linked with the haplotype causing an 
amino acid change on exon 3 of Ghiso gene (D 6 In tlO ) (Fig.9) and a 
silent polymorphism (D 6 In tl4 2 ) on exon 1 in Kras2 gene (Fig.10).
ATG
Ex 3
GCA GGC TAT 
GCA GAC TAT
D 6 In t lO
  Non-synonym ous and not linked
Figure 9 Amino-acid changing polymorphism in Ghisol. The boxes indicate 
the A/J (down) and C57BL6/J (on the top) sequence.
ATG
Ex 1
GGT CAT ACT 
GGT CGT ACT
D 6 In t l4 2
Synonymous
Figure 10 Polymorphism in Kras2. The boxes indicate the A/J (down) and 
C57BL6/J (on the top) sequence.
Lm na-rsl carries a E258G polymorphism (D6Int46 ) in exon 5 and a 
FI218S polymorphism (D6Int47) in exon 4. (Fig.11)
ATG
Ex 4 Ex 5
GGA CGC TCC 
GGA CAC TCC GAG GGA CAG GAG GAA CAG
D 6 In t4 7
D 6 In t4 6
Non-synonymous
Figure 11 Amino-acid polymorphism in Lmna-rsl. The boxes indicate the 
A/J (down) and C57BL6/J (on the top) sequence.
3.2 CANDIDATE GENES FUNCTIONAL ANALYSIS
I continued my project by testing functional activ ity of candidate 
genes in vitro in order to study possible effects of mouse genes in 
human cells as a step toward the application of findings in mice to 
humans.
3.2 .1  Allele-specific expression of candidate genes in mouse 
lung tumors
We carried out the expression analysis of the six candidate genes in 
four normal lungs of A/J and C57BL/6J mice, in five non-affected 
surrounding lung parenchyma of AB6F1 mice, and in nine urethane- 
induced lung tumors (3-5 mm in diameter) of AB6F1 hybrids.
We performed semiquantitative RT-PCR and we found that all the six 
genes are expressed at a sim ilar level in the normal mouse lung of 
A/J, C57BL/6J, and AB6F1 mice while we found some differences in 
the analysis of tum or samples. This analysis revealed that transcript 
levels were sim ilar for B ca tl, Cascl, Kras2, and Ghiso genes, while 
Lrmp showed a slightly reduced expression (about twofold) in six 
out of nine tumors. A difference in the expression was found in lung 
tumors where all genes but Lm na-rsl were expressed (Fig. 12)
This result suggests that Lm na-rs l may represent a putative new 
tum or suppressor gene or a cell-type differentiation marker, whose 
expression is restricted to specific lung cell types that do not give 
rise to lung tumors.
Normal T um or
Figure 12 mRNA expression of the Lmna-rsl (A) Ghiso (B) and Gapdh (C) 
genes in mouse normal lung and lung tumors by RT-PCR. Normal lungs 
derived from A/J (lanes 1, 2) and C57BL/6J (lanes 3, 4) mice. Lung tumors 
derived from AB6F1 mice (lanes 5-13).
Allele-specific expression patterns of Lrmp, Ghiso, Cascl, and Kras2 
genes were analyzed in normal lungs and tum ors from  AB6F1
Ihybrids. Lrmp and Ghiso revealed no allelic differences in expression 
in normal lungs or tumors of these mice. Expression of both Cascl 
alleles was detected in the normal lungs, but mono-allelic expression 
of the 60N allele deriving from the A/J lung tum or-susceptible 
parent was found in all tum or samples analyzed for the S60N 
polymorphism in exon 4 (D 6 In t4 1 ) (F ig .13), suggesting allele- 
specific silencing/activation of the Cascl gene in lung tumors.
A A G T G G  A R T C T G C  T G
Tumor
Normal
Figure 13 Representative nucleotide sequence pherograms of the Cascl 
gene by direct sequencing of RT-PCR products from normal lung and lung 
tumors of AB6F1 mice. Arrows indicate the mRNA expression of both A/J 
(green, A nt, 60N) and C57BL/6J (black, G nt, 60S) alleles in normal lung, 
whereas only the A/J allele is expressed in the lung tumors.
Analysis of Kras2 allele expression using the herein identified 
D 6 In t l4 2  SNP (A145635211G, Tyr32Tyr) (Acc. # AY490389) 
polymorphism located in exon 1 of th is gene revealed a s lightly 
preferential expression of the A/J as compared to the C57BL/6J 
allele (2- to 3-fold ratio) in the 9 tum or samples (not shown). All 
tumors carried a codon 61 Kras2 mutation (CAA^CTA in 5/9 tumors 
and CAA^CGA in the remaining 4 tum ors), but the mutated allele
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was expressed at heterozygosity in all tumors, with about 1:1 ratio 
of the wild-type to the mutated allele (Fig.14).
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Figure 14 Representative nucleotide sequence pherograms of the Kras2 
gene by direct sequencing of RT-PCR products from urethane-induced lung 
tumor of AB6F1 mice, showing the mRNA expression of both the wild-type 
codon 61 (CAA), codon 61 CTA mutation (panels B and D), and codon 61 
CGA mutation (panels A and C). Arrows indicate the position of the 
mutated nucleotide. Similar levels of wild-type and mutated codon 61 
mRNA expression were detected in tumors C and D, whereas the wild-type 
allele was more highly expressed in sample A, and sample B showed 
slightly higher levels of the mutated allele.
3.2 .1 .1  Functional ac tiv ity  of candidate genes in v itro : 
clonogenic assay
To evaluate the effects of Pasl candidates on cell proliferation, we 
carried out a series of transfection experim ents to determ ine 
whether these genes could promote or inh ib it grow th of two 
different human lung cell lines.
We in itia lly  tested the ab ility of the pEF6V5-Flis-TOPO vector to 
express recombinant candidate P asl genes in human cells. We
transfected the two alleles of the candidate genes in HEK-293T cells, 
that is a human epithelial cell line, which expressed high levels of 
transfected proteins. (Thomas and Smart, 2005 in Galbiati et a i ,  
2005). HEK-293T cells were transiently transfected with 5(ig 
recombinant plasmid DNA. After 24, 48 and 72h we pelleted the 
cells and then we extracted RNA. Candidate Pasl genes were RT- 
PCR-amplified with the primers used for subcloning. Analysis of 
mRNA expression revealed that all genes are well expressed and 
each allele is expressed at the same level at 24h, 48h and 72h after 
transfection. (Fig. 15)
Then we performed a Western blot analysis by transiently 
transfecting HEK-293T cells to confirm these data and to look for the 
corresponding protein expression.
Western blot analysis confirmed that Lm na-rsl, Ghiso, Lrmp and 
Cascl gene are well expressed 24, 48 and 72h after transfection and 
allowed us to find the corresponding protein expression of all genes.
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Figure 15 mRNA expression of Lmna-rsl (A), Ghiso (B), Lrmp (C) and 
Cascl (D) gene in HEK-293T cells. All genes are well expressed and each 
allele (A/J and C57BL/6J) is expressed at the same level 24-48 and 72h 
after transfection.
Once we demonstrated the capability of recombinant pEF6/V5-His- 
TOPO expression vector to express Pasl candidate proteins in 
human cells, we set up a stable transfection of two human lung
»
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cancer cell lines (A549 and NCI-H520 cells) with the same 
recombinant vectors for the clonogenicity assay analysis.
A549 and NCI-H520 cells seeded in 6-multi-well plates at 3 x l0 5 
cells/well were transfected with 2pg recombinant plasmid DNA and 4 
upl SuperFect (Qiagen) according to the manufacturer's protocol. 
Cells transfected with the empty vector were used as a control. Two 
days after transfection, the appropriate concentration of antibody 
was added and transfectant clones were selected after 17 days for 
A549 and 26 days for NCI-H520 cells. Blasticidin-resistant clones 
were either fixed with methanol (100% ) and stained with 10%  
Giemsa. We repeated at least three independent experiments.
The results obtained after the transfection of the two different cell 
lines were the same but the NCI-H520 cell line produces fewer and 
smaller clones than A549. The results were confirmed in all the 
experiments that we performed. The discrepancy in the size of 
clones is probably due to the different cells size and to the different 
cell grow rate.
In both A549 and NCI-H520 transfected cell lines, A/J and C57BL6/J 
alleles of candidate genes produced a variable number of clones. 
The number of clones of A/J and C57BL6/J alleles observed in Lrmp 
and Ghiso was the same and was similar to the vector alone (used 
as a control). While the A/J allele of Lm na-rs l produced more 
colonies than the C57BL6/J allele and the control (A and B in 
Fig. 16), the A/J allele of Cascl and the empty vector produced much 
fewer colonies than the C57BL6/J allele did (C and D in Fig. 16).
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Figure 16 Qualitative analysis of colony formation in human lung cancer 
cell transfectants. Giemsa-stained plates reveal in vitro allele-specific 
colony formation activities of mouse Lmna-rsl (A and B) or Cascl (C and 
D) in human lung carcinoma A549 (A and C) or NCI-H520 (B and D) cells 
transfected with these genes. Colony formation in both cell types was 
inhibited for the C57BL/6J allele of Lm na-rsl and for the A/J allele of 
Cascl.
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During the count, we decided to exclude colonies smaller than 0.5 
mm in diameter. The evaluation of the number of stained colonies 
was affected by this decision. Therefore, for a more quantitative 
evaluation, we decided to perform an analysis based on the count of 
the total number of blasticidin-resistant cells in each well.
A549 cells stably transfected with the A/J allele of Lmna-rsl 
produced 34.6±2.8 (mean±SE) xlO4 cells/well versus 9.0±0.4 xlO4 
cells/well produced by the C57BL/6 allele (P<0.0001). The same 
pattern was confirmed in NCI-H520 cells, with transfection of the A/J 
and the C57BL/6J allele producing 32.9±6.1 and 14.9±3.2 xlO4 
cells/well, respectively (P=0.020). A549 cells transfected with the 
Cascl A/J allele produced 4.2±0.7 versus 25.9±4.2 xlO 4 cells/well 
with the Cascl C57BL/6 allele, i.e., a 6-fold difference (P<0.0001). 
In NCI-H520 cells, transfection of the Cascl A/J allele produced 
5.3±1.1 versus 26.6+3.0 xlO4 cells/well produced by the C57BL/6 
allele, i.e., a 5-fold difference (P<0.0001).
No allele-specific effects were detected for Ghiso and Lrmp by cell 
count, in agreement with the qualitative observations of Giemsa- 
stained colonies. We found no differences between the two alleles 
when we transfected A549 and NCI-H520 cells. In particular, A549 
cells transfected with Lrmp alleles produced somewhat fewer (~  1.4- 
fold) numbers of cells/well (P<0.05), whereas Ghiso transfection 
showed no significant effects; in NCI-H520 cells, transfection with 
Lrmp led to a 4-fold reduction in the number of cells/well as 
compared to the empty vector transfection (P <0.0001). Ghiso 
transfection led to a 3-fold reduction in the number of cells/well as 
compared to the empty vector (P>0.0001). (Fig.17)
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Figure 17 Quantitative analysis of allele-specific colony formation in human 
lung carcinoma A549 (left) or NCI-H520 (right) cells. A/J and C57BL/6J 
alleles showed statistically significant differences. Transfection with the 
empty vector produced 66 x 104 and 128 x 104 A549 and NCI-H520 cells, 
respectively.
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3 .2 .2  Apoptosis analysis in candidate genes
We hypothesized that inhibition of clonogenicity by allelic forms of 
Cascl and Lmna-rsl genes was mediated by induction of apoptosis. 
Therefore, we tested whether PARP [Poly (ADP-ribose) polymerase] 
cleavage might underlie the allele-specific modulation of 
clonogenicity by candidate genes. PARP is a 116 kDa nuclear 
chromatin-associated enzyme and is a target of the caspase 
protease activity associated with apoptosis. During apoptosis PARP 
is cleaved from its 116 kDa intact form into 85 kDa and 25 kDa 
fragments. Apoptosis was analyzed in HEK-293T, A549, and NCI- 
H520 cells transiently transfected with A/J and C57BL/6J alleles of 
Casclf Lrmp, Ghiso and Lm na-rsl genes. After 24, 48 and 72 h, 
cells were lysed and a western blot experiment was performed. We 
used as a positive control anti-Fas (CD95)-treated ovarian cancer 
cells (OAW42)), and as a negative control OAW42 not treated as 
well as non transfected HEK-293T, A549, and NCI-H520 cell lines.
We expected the presence of the two fragments in A/J allele of 
Cascl and in C57BL6/J allele in Lmna-rsl.
Western blot analysis revealed no evidence that PARP was cleaved 
into the 85 kDa fragment at 48 or 72h after transfection of any of 
the candidate genes allelic variants. (Fig. 18)
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Figure 18 Apoptosis analysis in Lrmp (A), Lmna-rsl (B) and Cascl (C) by 
Western blotting in HEK-293T cell line for Lrmp and in A549 cell line for 
Lmna-rsl and for Cascl. Wild type cells were used as a negative control 
while anti-Fas (CD95)-treated ovarium cancer cells (OAW42) and not 
treated were used as a positive control. Our results revealed no evidence 
that PARP was cleaved at 48 and 72h after transfection of any of the 
candidate genes allelic variants.
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3.2 .3  Im m unofluorescence analysis
The immunofluorescence analysis was performed in HEK-293T cells 
tra n s ie n tly  transfected  w ith  calcium  phosphate 24h a fte r 
trans fec tion . The im m unofluorescence analysis revealed all 
recom binant P a s l candidate proteins localized m ainly in the 
cytoplasm.
Figure 19 Immunofluorescence staining of protein encoded by Lrmp 
candidate gene in HEK-293T cell line. Cells were transfected with A/J (A 
and C) and C57BL6/J (B and D) full length cDNAs, grown for 48h (A and B) 
and 72h (C and D) after transfection, fixed and treated with anti-V5 
monoclonal antibody followed by secondary antibody-Alexa Flour 488 
conjiugate. (Nikon Eclipse E1000 fluorescence microscope. Magnification: 
x40).
Lrmp (Fig. 19) and Ghiso (Fig.20) proteins were expressed at a very 
low level and in particular, Ghiso proteins were localized in small 
vacuoli around the nucleus.
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Figure 20 Immunofluorescence staining of protein encoded by Ghiso 
candidate gene in HEK-293T cell line. Cells were transfected with A/J (A 
and C) and C57BL6/J (B and D) full length cDNAs, grown for 48h (A and B) 
and 72h (C and D) after transfection, fixed and treated with anti-V5 
monoclonal antibody followed by secondary antibody-Alexa Flour 488 
conjiugate. (Nikon Eclipse E1000 fluorescence microscope. Magnification: 
x40).
Cascl and Lm n a-rs l proteins were expressed at a relatively high 
level. The Cascl (Fig.21) staining in the cytoplasm suggests that the 
protein is probably associated with the cytoskeleton fibers. While 
Lm na-rsl staining was uniformly diffuse (Fig.22)
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»Figure 21 Immunofluorescence staining of protein encoded by Cascl gene 
in HEK-293T cell line. Cells were transfected with A/J (A) and C57BL6/J (B) 
full length cDNAs, grown for 48h (A and B) and 72h (not shown) after 
transfection, fixed and treated with anti-V5 monoclonal antibody followed 
by secondary antibody-Alexa Flour 488 conjiugate. (Nikon Eclipse E1000 
fluorescence microscope. Magnification: x40).
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Figure 22 Immunofluorescence staining of protein encoded by Lmna-rsl 
candidate gene in HEK-293T cell line Cells were transfected with A/J (A 
and C) and C57BL6/J (B and D) full length cDNAs, grown for 48h (A and B) 
and 72h (C and D) after transfection, fixed and treated with anti-V5 
monoclonal antibody followed by secondary antibody-Alexa Flour 488 
conjiugate. (Nikon Eclipse E1000 fluorescence microscope. Magnification: 
x40 for A, B and C. Magnification: x20 for D.
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In the present study, we identified and genotyped 65 genetic 
markers in the Pasl locus region around Kras2 gene in a population 
of 29 laboratory mouse inbred strains with known susceptibility to 
lung carcinogenesis. This allowed us to construct a high-density 
Pasl haplotype map. The boundaries of the Pasl core haplotype 
were physically defined by the decay of its association to alleles at 
<145.346 Mb (D 6In t24) and at >145.815 Mb (D 6In t47 ) from the 
Chromosome 6 centromere. The distal boundary of the Pasl locus 
was also defined by a genetic recombination, which was nearly 
coincident with the haplotype boundary, in the CXB5 mouse line.
A/J- and C57BL/6J-type genetic variations segregated almost 
perfectly over the 468-kb haplotype region in the 29 laboratory 
strains. A recent study used A/J x C57BL/6 advanced intercross lines 
(AIL) to shorten the P asl locus interval, but it provided no 
advantage over LD analysis, since it suggested placement of the 
Pasl locus in a 1.3-Mb interval that includes the previous 0.45-Mb 
LD region and -27  known or predicted genes (Wang et al., 2003). 
Analysis of A/J x C57BL/6 congenic strains narrowed the Pasl locus 
interval to a 0.5-Mb region containing 12 putative genes (Zhang et 
al., 2003). Six of these 12 genes, chosen on the basis of mRNA 
expression in lungs, have been analyzed for coding polymorphisms 
and in vitro allelic effects; five of the six genes showed no allelic- 
specific effects in vitro and their candidacy was excluded. However, 
that study cannot be considered conclusive since these five 
expressed genes might also modulate lung tumorigenesis by 
mechanisms other than those affecting tumor growth (Hanahan & 
Weinberg, 2000).
We directed our attention to six putative Pasl candidate genes that 
map in this 468-kb region. The biological or biochemical functions of 
most of these genes are unknown:
B c a tl: maps to location 145.845604-145.895256. It  has 11 exons 
and the transcript length is 2,508 bps.
This gene encodes the cytosolic form of the enzyme 
branched-chain amino acid transaminase and catalyzes the 
first step of branched-chain amino acid catabolism. This 
enzyme catalyzes the reversible transamination of branched- 
chain alpha-keto acids to branched-chain L-amino acids 
essential for cell growth. Two different clinical disorders have 
been attributed to a defect of branched-chain amino acid 
transam ination: hypervalinem ia and hyperleucine-
isoleucinemia. As there is also a gene encoding a 
mitochondrial form of this enzyme, mutations in either gene 
may contribute to these disorders. Furthermore, Bcatl 
appears to be involved in apoptosis (Eden and Benvenisty, 
1999).
Lrmp: maps to location 145.968258-146.021372. It  has 19 exons 
and the transcript length is 2,238 bps.
The lymphoid-restricted membrane protein encoded by this 
gene has 539 residues and it is expressed in a 
developmentally regulated manner in lymphoid cell lines and 
tissues. The protein is localized to the cytoplasmic face of the 
endoplasmic reticulum and has a coiled-coil domain in the 
middle-third of the protein and a carboxyl-terminal 
membrane anchor (Behrens et al 1994).
Lrmp expression was originally described as lymphoid cell- 
specific, with highest expression levels in pre-T, pre-B, and 
mature B cells (Behrens et al., 1994). However, we detected 
significant Lrmp expression levels in lung tumors (not 
shown); clarification of whether Lrmp expression occurs in 
normal epithelial lung cells or is instead restricted to lung- 
associated lymphoid cells awaits immunohistochemical 
analysis of normal lung. The Jawl-homologous protein Mrvil,
mapping to Chromosome 7, causes leukemia in mice upon 
activation by retroviral integration (Shaughnessy, Jr. et al., 
1999), suggesting an important role for this class of integral 
membrane proteins in cancer and, possibly, for Lrm p  
polymorphisms in lung cancer susceptibility. The role of 
lymphoid cells and, more widely, of the immune system in 
lung tumorigenesis is suggested by enhancement of lung 
adenoma formation in neonatally thymectomized mice 
treated with 7,12-dimethylbenz(a)anthracene or urethane 
(Trainin et al., 1967). Moreover, splenectomy inhibited 
DMBA-induced lung tumor incidence in mice (Akamatsu, 
1975), and inflammation is a known modulator of tumor 
development, both in mice and humans (Brownson & 
Alavanja, 2000; Mayne et al., 1999; Askling et al., 1999; 
Bauer et al., 2001).
The role of the Lrmp gene in lung tumorigenesis is not 
known; this gene is involved in antigen processing (Snyder et 
al., 1997).
Cascl: this gene corresponds to the recently identified gene (Acc. #  
AY423542) (Zhang et al., 2003). Our Cascl transcript (Acc. 
# AY485607, AY485608), compared to the AY423542 
transcript, is 70 bp longer in the 5'-UTR, most likely 
represents the full-length transcript of the gene. We 
identified and then cloned Cascl using a different program to 
identify coding regions in the genome (N IX analysis 
package). Cascl has 16 exons, spans a 36-kb region, and is 
flanked at its 3'-end by the 3'-end of Lrmp and at its 5'-end 
by the 5'-end of Ghiso.
A study at multiple-organ expression panels (Zhang 2003) 
found that Cascl was expressed at higher levels in lung, 
testis and kidney in both A/J and C57BL/6J strains. They 
studied the cellular localization of Cascl product in three
89
different cell lines and found a cytoplasmic distribution. In 
the same study, Cascl showed allelic-specific effects in vitro 
and in a tumor growth assay in nude mice, and was proposed 
as the candidate Pasl gene. Cascl protein is 67% identical 
and 81% similar to the derived human CASC1 protein (similar 
to human hypothetical protein FU10921, 30.41 Mb). Analysis 
of the putative secondary structure of the Cascl encoded 
protein predicted a coiled-coil domain in its N-terminal region 
( a m i n o  a c i d s  9 - 5 9 )
(http://www.ch.embnet.org/software/COILS_form.html). The 
coiled-coil structure is one of the principal oligomerization 
motifs in proteins (Burkhard et al., 2001). This similarity, 
with the Lrmp encoded protein, suggests that the two 
proteins may either interact with each other or with a 
common substrate.
Ghiso: (also named 4930469P12Rik) maps to location 146.057600- 
146.063383, has 3 exons and its transcript length is 2,436 
bps. This gene encodes a growth hormone-inducible soluble 
protein (AF412299) (of 86 residues) with no known protein 
domain therefore it was previously named Ghiso. Ghiso's 
intragenic polymorphisms play a functional role in lung tumor 
susceptibility.
The upstream intragenic regions of both Cascl and Ghiso 
genes consist of a common 176-bp genomic fragment that, in 
light of its short length and the flanking of the 5'-ends of two 
genes, might share a bidirectional promoter activity.
KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog maps 
at location 145.307569-145.341093, has 5 exons and its 
transcript length is 752 bps. This gene, a Kirsten ras 
oncogene homolog from the mammalian ras gene family, 
encodes a protein that is a member of the small GTPase
90
superfamily. A single amino acid substitution results in a 
transforming protein implicated in various malignancies, 
including lung adenocarcinoma, mucinous adenoma, ductal 
carcinoma of the pancreas and colorectal carcinoma. 
Alternative splicing leads to variants encoding two isoforms 
that differ in the C-terminal region. Somatic mutations of the 
Kras2 gene play a causal role in lung tumorigenesis (Johnson 
et al., 2001) and have also been found in chronic 
inflammation conditions, such as chronic pancreatitis and 
ulcerative colitis (Yanagisawa et al., 1993; Lang et al., 1999). 
A transgenic mouse expressing the human c-H-ras gene 
showed enhanced susceptibility to autoimmune hepatitis 
(Tsunematsu et al., 1997). Thus, the Kras2 gene may be a 
candidate for both lung tumor susceptibility and inflammatory 
response.
Genomic Kras2  polymorphisms might modulate gene 
mutability and, in turn, numbers of tumors after chemical 
carcinogen treatment. The functional involvement of Kras2 in 
lung tumorigenesis has been demonstrated for its wild-type 
(Zhang et al., 2001) and mutated alleles, which we found 
expressed at an almost perfect 1:1 ratio in lung tumors, in 
contrast with the reported loss of heterozygosity of the wild- 
type Kras2 allele in mouse lung tumors (Zhang et al., 2001).
L m n a - r s l :  (also named 4933403M22Rik) maps to location 
146.244904-146.286944, it has 9 exons and the transcript 
length is 1,514 bps.
Protein sequence comparison by BLAST showed that this 
gene encodes a protein (of 413 residues) containing an 
intermediate filament tail domain related to lamin A. For this 
reason the gene was previously named Lmna-rsl (lamin A- 
related sequence 1). It  may be a tumor suppressor. Amino-
acid changes and down regulation are associated with lung 
adenoma susceptibility.
4.1 Pasl haplotype
The haplotype of the Pasl region defined strain relatedness in which 
the laboratory strains resolved as two groups according to the A/J- 
and the C57BL/6J-type haplotype, respectively.
This finding indicates that the Pasl QTL is due to an ancestral 
difference common to many laboratory strains rather than to a rare 
mutation specific to a single strain (Manenti et al., 1999).
Recent studies indicate that regions of low SNP density (-0 .5  SNPs 
per 10 kb) are separated by regions of high density (-40  SNPs per 
10 kb), creating a mosaic structure of genetic variations in mice and 
defining haplotype blocks of an average size of 1 Mb (Wade et al., 
2002; Wiltshire et al., 2003). Laboratory strain haplotypes 
recapitulate population history of these strains and identify strain 
relatedness (Wiltshire et al., 2003). The Pasl core haplotype showed 
a high frequencies of polymorphisms (-100 SNPs/SSLPs per 10 kb) 
but resulted in only two haplotype-types. The P asl-derived strain 
grouping was very different from that defined by whole-genome 
analysis of SNPs in mouse strains, which reflects strain genealogy 
(Wiltshire et al., 2003). Indeed, unlike the strain relatedness of the 
Pasl locus, whole-genome SNP analysis placed strains carrying the 
A/J- and C57BL/6J-type haplotype at the Pasl locus close together 
(see Fig. 4D of Wiltshire et al., 2003), where RF/J and AKR/J, CBA/J 
and C3H, SWR/J and SJL/J strains are placed in the same sub­
branches. Therefore, the Pasl haplotype is not the product of strain 
genealogy.
In addition, 12/54 (22% ) markers located within the haplotype did 
not cosegregate with the haplotype, suggesting that recombination
had taken place during the creation of the haplotype block and that
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linkage disequilibrium between the haplotype and non-essential 
polymorphisms has been lost, respectively, and two silent 
polymorphisms in the coding region of the Lrmp (D 6In t32c ) and 
Kras2 gene (D 6In tl42 ).
Within the haplotype block, five amino-acid changes in three genes 
showed tight linkage with the haplotype (Tab. 8) and produced 
nonconservative changes.
The effect of any polymorphism on protein function relies not only 
on the type of change, but also on where the change occurs. For 
example, a change in a substrate binding site domain seems more 
likely to affect protein biochemical activity than a change in a non- 
critical domain. In any case, the prediction of a functional effect of 
any amino acid change awaits experimental evidence to distinguish 
the functional variations from the thousands of non functional 
genetic variations identified so far.
As the amino acid polymorphisms of three genes (Lrmp, Cascl, and 
Lmna-rsl), as well as intragenic polymorphisms of the Bcatl, Ghiso, 
and Kras2 genes, are tightly linked in a single haplotype type, we 
cannot exclude any of these six genes as putative Pasl candidate 
genes. Moreover, 7 intergenic and 29 intragenic polymorphisms 
showed a tight linkage with the Pasl haplotype (Tab. 8).
We found that A/J and C57BL/6J alleles of recombinant Lrmp protein 
are distinguished by three amino acid variations, including L537P 
(D 6In t8 ), which shows tight linkage not only with the Pasl locus 
haplotype, but also with susceptibility to an inflammatory response 
in a phenotypically selected mouse line. Because Lrmp encodes the 
Jaw protein, which is overexpressed in pre-T, pre-B, and mature B 
cells (Behrens et al., 1994), this gene might have a role in the 
inflammatory response.
The G28D (D6IntlO) polymorphism that we studied in Ghiso showed 
no significant linkage with Pasl locus activity or with inflammatory 
response.
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These two genes showed no allelic differences in expression in 
normal mouse lungs or lung tumors, whereas Cascl showed 
preferential expression in lung tumors of the A/J-derived allele.
4 .2 Candidate genes functional analysis
We decided to verify the hypothesis that the Pasl locus is comprised 
of a cluster of six cancer modifier genes in the in vitro study of 
these candidate genes.
Ghiso carries an amino-acid polymorphism that does not 
cosegregate with mouse lung tumor susceptibility, nevertheless we 
decided to include Ghiso in the in vitro study because the genomic 
structure of the 5' UTR region of Cascl and Ghiso are separated by 
169 bp suggesting that they might share a unique bidirectional 
promoter and/or other regulatory elements.
By assaying the putative cancer modifier function of Pasl candidate 
genes in human lung cancer cell lines of different histotype origin 
and with different morphological and growth characteristics, we 
sought to provide clues into the possible effects of mouse genes in 
human cells as a step toward the application of findings in mice to 
humans.
Colony formation assay of cancer cell lines expressing allelic variants 
of candidate cancer modifier genes by transfection represents a 
convenient method of assessing functional in vitro activity of allelic 
variants, since the number of resulting colonies provides an estimate 
of the growth or survival of transfected cancer cells.
Results obtained by semi-quantitative Giemsa-stained colony 
formation were consistent with those obtained by cell count assay in 
both human lung cancer cell lines. The amino acid variants of Lrmp 
and Ghiso genes showed no significant differences in the number of
transfected colonies and cells, whereas Cascl and Lmna-rsl showed 
significant differences in allelic effects.
The observed lack of differential effects between the A/J and 
C57BL/6J alleles of the Lrmp and Ghiso genes on colony formation 
of transfected human cancer cell lines is consistent with previous 
observations in mouse cell lines obtained by Zhang et al. in 2003. 
Our findings of a growth inhibitory effect of Cascl for A/J versus the 
C57BL/6J allele contrasts with findings by Zhang et al. in 2003, who 
instead found a stimulatory effect of the A/J Cascl in mouse cell 
lines. Since the recombinant transcripts used in both studies contain 
the same full-length coding regions of Cascl, there are no obvious 
explanations for the discrepant findings other than different somatic 
changes or difference species in the cell lines used. We obtained 
concordant results in two human lung cancer cell lines with a 
different KRAS mutation status: A549 cells carries a Gly->Ser 
mutation at the codon 12 of the KRAS gene (Valenzuela and 
Groffen, 1986), whereas NCI-H520 cells carries no KRAS mutation 
at codon 12 or 13 (data not shown).
We found allelic effects for the Lmna-rsl with a growth stimulatory 
effect of the A/J allele, whereas Zhang et al. in 2003 reported no 
allelic differences for the same full-length transcript that we 
assayed. However, the same authors recently reported the 
stimulatory effect of an A/J-specific mRNA isoform of Lm na-rsl in 
NIH mouse fibroblast cell lines (Whang et al., 2005). Lmna-rsl may 
be a cell-type differentiation marker, whose expression is restricted 
to specific lung cell types that do not give rise to lung tumors.
We found that Lm na-rs l gene expression is not detectable in 
primary mouse lung tumors. These results suggest that Lmna-rsl is 
expressed in the early stages of lung tumorigenesis and becomes 
down regulated during tumor growth, so that the A/J allele may 
stimulate growth of initiated neoplastic cells, thus contributing to the 
effects of the Pasl locus.
In vitro assays cannot detect all the possible gene effects on 
tumorigenesis, which is a complex phenomenon involving tumor- 
host interactions modulated by numerous factors. After transfection 
of either the Lmna-rsl or Cascl allele we can exclude that inhibition 
of clonogenicity in vitro by allelic forms of Pasl candidate genes is 
mediated by apoptosis.
Further studies are needed to clarify the precise mechanisms of 
allele-specific in vitro effects of these two genes.
4.3 In flam m atory response
Lrmp, Bcatl, and Kras2 have been associated with apoptosis, tumor 
development and inflammatory response (Eden & Benvenisty, 1999; 
Johnson et al., 2001; Maria et al., 2003).
In Maria 2003 it was shown that mouse outbred lines phenotypically 
selected for high (AIRmax) and low (AIRmm) response to s.c. 
nonspecific acute inflammation showed dramatic differences in their 
susceptibility to lung tumorigenesis. In particular AIRmin mice were 
~40-fold more susceptible than AIRmax mice. It  was found that in 
AIR lines there is a correlation between persistent subacute lung 
inflammation and susceptibility to lung tumorigenesis. LD analysis in 
AIR lines was performed using genetic markers located within the 
Pasl locus to assess the possible involvement of the Pasl locus in 
the inflammatory response. Markers located within a 452-kb Pasl 
region showed a highly significant LD pattern (-log P>8.0). Markers 
outside this region showed either nonsignificant or borderline LD 
values, indicating that the location of the gene(s) responsible for the 
AIR phenotype lies within this 452-kb region. The results of this 
work indicate that a genetic polymorphism(s) of at least one of the 
five genes is functionally responsible for the P as l and AIR 
phenotypes.
4 .4  Conclusion
The demonstration of allele-specific in vitro effects in human lung 
cancer cell lines of two of the four genes that carry amino acid 
variants and are included in the Pasl haplotype provides evidence 
that alleles of mouse candidate cancer modifier genes can modulate 
growth of human cancer cells. Overall, the in vitro effects of the A/J 
allele of the Cascl gene, unlike the in vivo effects of the Pasl 
haplotype in stimulating lung tumor development, and the absence 
of in vitro modulation activity of the L rm p  gene whose 
polymorphisms are tightly linked with the Pasl haplotype, support 
the possibility of a functional role for the whole Pasl haplotype, and 
not just of the individual genes comprising it, in determining genetic 
predisposition to lung cancer.
The results obtained in this work suggest that Pasl locus is 
comprised of a cluster of six cancer modifier genes, whose amino- 
acid and genomic polymorphisms operate to confer susceptibility or 
resistance to lung tumorigenesis.
Zhang et al. in 2003 proposed the Cascl gene as the Pasl gene. 
Moreover, in their study, genetic recombination did not separate the 
Cascl gene from the other five genes of the herein identified Pasl 
haplotype, confirming our hypothesis that none of the six genes can 
yet be formally excluded from Pasl candidacy.
4.5 Future aims
In conclusion, we achieved the aims of the project and now we 
continue to study the candidate genes.
First, we will study the putative bidirectional promoter that maps in 
the 169 bp region between Cascl and Ghiso by subcloning this 
region in pGL3 Luciferase Reporter Vector. pGL3 Vectors provide a 
basis for the quantitative analysis of factors that potentially regulate 
mammalian gene expression and contain a modified coding region 
for firefly (Photinus pyralis) luciferase that has been optimized for 
monitoring transcriptional activity in transfected eukaryotic cells.
Preliminary data, obtained in our laboratory, shown that C ascl, 
Kras2 and Lmna-rsl genes give rise to a series of isoforms. Probably 
qualitative and quantitative variations of these isoforms might 
modulate the different susceptibility to lung carcinogenesis in mice. 
We will carried out an expression analysis of the different isoforms 
and then we will test their functional activity in vitro.
Our in vitro assays cannot detect all possible gene effects on 
tumorigenesis, which is a complex phenomenon involving tumor- 
host interactions modulated by numerous factors (Hanahan and 
Weinberg, 2000). Therefore, we will test tumor growth in vivo and 
then clone the human homologous genes, caring out an analysis of 
association between genetic polymorphism and lung 
adenocarcinoma risk and prognosis in a human population.
Then we will perform a detailed genetic analysis of the homologous 
human region in lung adenocarcinoma patients and healthy 
population controls. This might determine whether specific 
haplotypes also occur in humans and whether they control lung 
cancer risk.
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